<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-title>Lipids in Health and Disease</journal-title><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17274828</article-id><article-id pub-id-type="pmc">1800848</article-id><article-id pub-id-type="publisher-id">1476-511X-6-4</article-id><article-id pub-id-type="doi">10.1186/1476-511X-6-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Oben</surname><given-names>Julius E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>juliusoben@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Enyegue</surname><given-names>Damaris Mandob</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>damand04@yahoo.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Fomekong</surname><given-names>Gilles I</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fdogines@yahoo.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Soukontoua</surname><given-names>Yves B</given-names></name><email>soukyberto@yahoo.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Agbor</surname><given-names>Gabriel A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>agoga@yahoo.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>Laboratory of Nutrition and Nutritional Biochemistry, Department of Biochemistry, B.P. 812, University of Yaoundé I, Yaoundé, Cameroon</aff><aff id="I2"><label>2</label>CRPMT, Institute of Medical Research and Medicinal Plants Studies, Yaoundé, Cameroon</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>4</day><month>2</month><year>2007</year></pub-date><volume>6</volume><fpage>4</fpage><lpage>4</lpage><ext-link ext-link-type="uri" xlink:href="http://www.lipidworld.com/content/6/1/4"></ext-link><history><date date-type="received"><day>15</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2007</year></date></history><permissions><copyright-statement>Copyright © 2007 Oben et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Oben et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3407" xml_f="3410" txt_i="11" txt_f="14">Aim</offsets></title><p><offsets xml_i="3421" xml_f="3584" txt_i="15" txt_f="178">Obesity is generally linked to complications in lipid metabolism and oxidative stress. The aim of this study was to compare the effect of a proprietary extract of </offsets><italic><offsets xml_i="3592" xml_f="3614" txt_i="178" txt_f="200">Cissus quadrangularis </offsets></italic><offsets xml_i="3623" xml_f="3773" txt_i="200" txt_f="350">(CQR-300) to that of a proprietary formulation containing CQR-300 (CORE) on weight, blood lipids, and oxidative stress in overweight and obese people.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3814" xml_f="3821" txt_i="352" txt_f="359">Methods</offsets></title><p><offsets xml_i="3832" xml_f="3877" txt_i="360" txt_f="405">The first part of the study investigated the </offsets><italic><offsets xml_i="3885" xml_f="3894" txt_i="405" txt_f="414">in vitro </offsets></italic><offsets xml_i="3903" xml_f="4429" txt_i="414" txt_f="940">antioxidant properties of CQR-300 and CORE using 3 different methods, while the second part of the study was a double-blind placebo controlled design, involving initially 168 overweight and obese persons (38.7% males; 61.3% females; ages 19–54), of whom 153 completed the study. All participants received two daily doses of CQR-300, CORE, or placebo and were encouraged to maintain their normal levels of physical activity. Anthropometric measurements and blood sampling were done at the beginning and end of the study period.</offsets></p></sec><sec><title><offsets xml_i="4451" xml_f="4458" txt_i="942" txt_f="949">Results</offsets></title><p><offsets xml_i="4469" xml_f="4526" txt_i="950" txt_f="1007">CQR-300 as well as CORE exhibited antioxidant properties </offsets><italic><offsets xml_i="4534" xml_f="4542" txt_i="1007" txt_f="1015">in vitro</offsets></italic><offsets xml_i="4551" xml_f="4572" txt_i="1015" txt_f="1036">. They also acted as </offsets><italic><offsets xml_i="4580" xml_f="4588" txt_i="1036" txt_f="1044">in vivo </offsets></italic><offsets xml_i="4597" xml_f="5011" txt_i="1044" txt_f="1455">antioxidants, bringing about significant (p &lt; 0.001) reductions in plasma TBARS and carbonyls. Both CQR-300 and CORE also brought about significant reductions in weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, and fasting blood glucose levels over the respective study periods. These changes were accompanied by a significant increase in HDL-cholesterol levels, plasma 5-HT, and creatinine.</offsets></p></sec><sec><title><offsets xml_i="5033" xml_f="5043" txt_i="1457" txt_f="1467">Conclusion</offsets></title><p><offsets xml_i="5054" xml_f="5407" txt_i="1468" txt_f="1821">CQR-300 (300 mg daily) and CORE (1028 mg daily) brought about significant reductions in weight and blood glucose levels, while decreasing serum lipids thus improving cardiovascular risk factors. The increase in plasma 5-HT and creatinine for both groups hypothesizes a mechanism of controlling appetite and promoting the increase of lean muscle mass by </offsets><italic><offsets xml_i="5415" xml_f="5436" txt_i="1821" txt_f="1842">Cissus quadrangularis</offsets></italic><offsets xml_i="5445" xml_f="5536" txt_i="1842" txt_f="1933">, thereby supporting the clinical data for weight loss and improving cardiovascular health.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5598" xml_f="5608" txt_i="1942" txt_f="1952">Background</offsets></title><p><offsets xml_i="5619" xml_f="6097" txt_i="1953" txt_f="2431">The incidence of obesity in adults as well as children is on an increase globally. Once considered a problem of developed countries, this global epidemic also affects developing countries. Coupled to this epidemic are obesity-related complications such as cardiovascular disease, stroke, depression, and Type-2 diabetes, which are spreading rapidly across poor and middle-income countries, where infectious diseases and malnutrition have previously overshadowed such illnesses [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6128" xml_f="6129" txt_i="2431" txt_f="2432">1</offsets></xref><offsets xml_i="6136" xml_f="6202" txt_i="2432" txt_f="2498">]. Obesity is a principal causative factor of metabolic syndrome [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6233" xml_f="6234" txt_i="2498" txt_f="2499">2</offsets></xref><offsets xml_i="6241" xml_f="6242" txt_i="2499" txt_f="2500">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6273" xml_f="6274" txt_i="2500" txt_f="2501">6</offsets></xref><offsets xml_i="6281" xml_f="6458" txt_i="2501" txt_f="2678">]. The coexistence of these metabolic syndromes (hyperglycemia, dyslipidemia, and hypertension in the same individual) is a growing medical problem in industrialized countries [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6489" xml_f="6490" txt_i="2678" txt_f="2679">6</offsets></xref><offsets xml_i="6497" xml_f="6498" txt_i="2679" txt_f="2680">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6529" xml_f="6530" txt_i="2680" txt_f="2681">9</offsets></xref><offsets xml_i="6537" xml_f="6756" txt_i="2681" txt_f="2900">]. It has been reported that obesity may induce systemic oxidative stress and that increased oxidative stress in accumulated fat is associated with dysregulation of adipocytokines and development of metabolic syndrome [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6787" xml_f="6788" txt_i="2900" txt_f="2901">6</offsets></xref><offsets xml_i="6795" xml_f="6878" txt_i="2901" txt_f="2984">]. Oxidative stress has been shown to be involved in the process of atherogenesis [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6910" xml_f="6912" txt_i="2984" txt_f="2986">10</offsets></xref><offsets xml_i="6919" xml_f="6946" txt_i="2986" txt_f="3013">], ischemic heart disease [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6978" xml_f="6980" txt_i="3013" txt_f="3015">11</offsets></xref><offsets xml_i="6987" xml_f="6999" txt_i="3015" txt_f="3027">], obesity [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7030" xml_f="7031" txt_i="3027" txt_f="3028">6</offsets></xref><offsets xml_i="7038" xml_f="7085" txt_i="3028" txt_f="3075">], metabolic syndrome or syndrome X, diabetes [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7117" xml_f="7119" txt_i="3075" txt_f="3077">12</offsets></xref><offsets xml_i="7126" xml_f="7127" txt_i="3077" txt_f="3078">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="7159" xml_f="7161" txt_i="3078" txt_f="3080">13</offsets></xref><offsets xml_i="7168" xml_f="7203" txt_i="3080" txt_f="3115">], as well as in immunodeficiency [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="7235" xml_f="7237" txt_i="3115" txt_f="3117">14</offsets></xref><offsets xml_i="7244" xml_f="7379" txt_i="3117" txt_f="3252">]. The stability of tissues against oxidative stress is however enhanced by antioxidant compounds, which could be present in the diet [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="7411" xml_f="7413" txt_i="3252" txt_f="3254">15</offsets></xref><offsets xml_i="7420" xml_f="7573" txt_i="3254" txt_f="3407">]. Antioxidants have also been shown to be very effective in inhibiting the oxidation of LDL and scavenging of free radicals and reactive oxygen species </offsets><italic><offsets xml_i="7581" xml_f="7590" txt_i="3407" txt_f="3416">in vitro </offsets></italic><offsets xml_i="7599" xml_f="7600" txt_i="3416" txt_f="3417">[</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="7632" xml_f="7634" txt_i="3417" txt_f="3419">16</offsets></xref><offsets xml_i="7641" xml_f="7642" txt_i="3419" txt_f="3420">-</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="7674" xml_f="7676" txt_i="3420" txt_f="3422">20</offsets></xref><offsets xml_i="7683" xml_f="7826" txt_i="3422" txt_f="3565">]. These compounds are present in fruits and vegetables, which contain natural antioxidants, and are known to delay the onset of atherogenesis.</offsets></p><p><italic><offsets xml_i="7841" xml_f="7863" txt_i="3566" txt_f="3588">Cissus quadrangularis </offsets></italic><offsets xml_i="7872" xml_f="8334" txt_i="3588" txt_f="4050">(Linn) has been used by common folk in India for promoting the fracture healing process. It has been prescribed in Ayurveda as an alterative, anthelmintic, dyspeptic, digestive, tonic, analgesic in eye and ear diseases, and in the treatment of irregular menstruation and asthma. In Cameroon, the whole plant is used in oral re-hydration, while the leaf, stem, and root extracts of this plant are important in the management of various ailments. Earlier works on </offsets><italic><offsets xml_i="8342" xml_f="8364" txt_i="4050" txt_f="4072">Cissus quadrangularis </offsets></italic><offsets xml_i="8373" xml_f="8481" txt_i="4072" txt_f="4180">report its effectiveness on the management of obesity and complications associated with metabolic syndrome [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="8513" xml_f="8515" txt_i="4180" txt_f="4182">21</offsets></xref><offsets xml_i="8522" xml_f="8589" txt_i="4182" txt_f="4249">], as well as its antioxidant and free radical scavenging activity </offsets><italic><offsets xml_i="8597" xml_f="8606" txt_i="4249" txt_f="4258">in vitro </offsets></italic><offsets xml_i="8615" xml_f="8616" txt_i="4258" txt_f="4259">[</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="8648" xml_f="8650" txt_i="4259" txt_f="4261">22</offsets></xref><offsets xml_i="8657" xml_f="8658" txt_i="4261" txt_f="4262">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="8690" xml_f="8692" txt_i="4262" txt_f="4264">23</offsets></xref><offsets xml_i="8699" xml_f="8747" txt_i="4264" txt_f="4312">]. Various formulations now contain extracts of </offsets><italic><offsets xml_i="8755" xml_f="8777" txt_i="4312" txt_f="4334">Cissus quadrangularis </offsets></italic><offsets xml_i="8786" xml_f="9010" txt_i="4334" txt_f="4558">in combination with other compounds, used for the purpose of management of overweight and obesity, as well as complications resulting from these conditions, notably metabolic syndrome (syndrome X). Phytochemical analyses of </offsets><italic><offsets xml_i="9018" xml_f="9040" txt_i="4558" txt_f="4580">Cissus quadrangularis </offsets></italic><offsets xml_i="9049" xml_f="9336" txt_i="4580" txt_f="4867">revealed high contents of ascorbic acid, carotene, anabolic steroidal substances, and calcium. The stem contains two asymmetric tetracyclic triterpenoids, and two steroidal principles. The presence of β-sitosterol, δ-amyrin, δ-amyrone, and flavanoids (quercetin) has also been reported [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="9368" xml_f="9370" txt_i="4867" txt_f="4869">24</offsets></xref><offsets xml_i="9377" xml_f="9378" txt_i="4869" txt_f="4870">,</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="9410" xml_f="9412" txt_i="4870" txt_f="4872">25</offsets></xref><offsets xml_i="9419" xml_f="9506" txt_i="4872" txt_f="4959">], all these components having potentially different metabolic and physiologic effects.</offsets></p><p><offsets xml_i="9513" xml_f="9540" txt_i="4960" txt_f="4987">Although different uses of </offsets><italic><offsets xml_i="9548" xml_f="9570" txt_i="4987" txt_f="5009">Cissus quadrangularis </offsets></italic><offsets xml_i="9579" xml_f="9604" txt_i="5009" txt_f="5034">have been investigated, [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="9636" xml_f="9638" txt_i="5034" txt_f="5036">26</offsets></xref><offsets xml_i="9645" xml_f="9646" txt_i="5036" txt_f="5037">,</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="9678" xml_f="9680" txt_i="5037" txt_f="5039">27</offsets></xref><offsets xml_i="9687" xml_f="9726" txt_i="5039" txt_f="5078">] the antioxidant potential of various </offsets><italic><offsets xml_i="9734" xml_f="9756" txt_i="5078" txt_f="5100">Cissus quadrangularis </offsets></italic><offsets xml_i="9765" xml_f="9925" txt_i="5100" txt_f="5260">formulations have not been evaluated in the modulation of obesity-induced oxidative stress. It was for this reason that the present study was designed, using a </offsets><italic><offsets xml_i="9933" xml_f="9955" txt_i="5260" txt_f="5282">Cissus quadrangularis </offsets></italic><offsets xml_i="9964" xml_f="10022" txt_i="5282" txt_f="5340">formulation (CORE) and CQR-300 (a standardized extract of </offsets><italic><offsets xml_i="10030" xml_f="10051" txt_i="5340" txt_f="5361">Cissus quadrangularis</offsets></italic><offsets xml_i="10060" xml_f="10112" txt_i="5361" txt_f="5413">, 2.5 % keto-steroids, and 15% soluble plant fiber).</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10153" xml_f="10160" txt_i="5415" txt_f="5422">Methods</offsets></title><p><offsets xml_i="10171" xml_f="10468" txt_i="5423" txt_f="5720">The study was approved by the Cameroon National Ethics Board. The purpose, nature, and potential risks of the study were explained to all participants, who gave their written informed consent before participation. The study was conducted in accordance with the Helsinki Declaration (1983 version).</offsets></p><sec><title><offsets xml_i="10484" xml_f="10490" txt_i="5721" txt_f="5727">Sample</offsets></title><p><offsets xml_i="10501" xml_f="10513" txt_i="5728" txt_f="5740">CORE (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="10545" xml_f="10546" txt_i="5740" txt_f="5741">1</offsets></xref><offsets xml_i="10553" xml_f="10653" txt_i="5741" txt_f="5841">) was obtained from Soy Labs, LLC., Fairfield, California, USA;. CQR-300, a standardized extract of </offsets><italic><offsets xml_i="10661" xml_f="10683" txt_i="5841" txt_f="5863">Cissus quadrangularis </offsets></italic><offsets xml_i="10692" xml_f="10810" txt_i="5863" txt_f="5981">containing 2.5% keto-steroids and 15% soluble plant fiber (Gateway Health Alliances, Inc, Fairfield, California, USA).</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="10858" xml_f="10865" txt_i="5982" txt_f="5989">Table 1</offsets></label><caption><p><offsets xml_i="10885" xml_f="10939" txt_i="5989" txt_f="6043">Detailed composition of the cissus formulation (CORE).</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="11018" xml_f="11022" txt_i="6044" txt_f="6048">Item</offsets></td><td align="left"><offsets xml_i="11044" xml_f="11055" txt_i="6049" txt_f="6060">Description</offsets></td><td align="left"><offsets xml_i="11077" xml_f="11107" txt_i="6061" txt_f="6091">Active Amount Per Capsule (mg)</offsets></td><td align="left"><offsets xml_i="11129" xml_f="11171" txt_i="6092" txt_f="6134">Amount of Active Per Day (2 capsules) (mg)</offsets></td></tr></thead><tbody><tr><td align="left"><italic><offsets xml_i="11225" xml_f="11246" txt_i="6135" txt_f="6156">Cissus quadrangularis</offsets></italic></td><td align="left"><offsets xml_i="11277" xml_f="11292" txt_i="6157" txt_f="6172">5% ketosteroids</offsets></td><td align="left"><offsets xml_i="11314" xml_f="11317" txt_i="6173" txt_f="6176">7.5</offsets></td><td align="left"><offsets xml_i="11339" xml_f="11341" txt_i="6177" txt_f="6179">15</offsets></td></tr><tr><td align="left"><offsets xml_i="11372" xml_f="11383" txt_i="6180" txt_f="6191">ChromeMate*</offsets></td><td align="left"><offsets xml_i="11405" xml_f="11449" txt_i="6192" txt_f="6236">Niacin-Bound Chromium (10% Cr) – Concentrate</offsets></td><td align="left"><offsets xml_i="11471" xml_f="11475" txt_i="6237" txt_f="6241">0.15</offsets></td><td align="left"><offsets xml_i="11497" xml_f="11500" txt_i="6242" txt_f="6245">0.3</offsets></td></tr><tr><td align="left"><offsets xml_i="11531" xml_f="11564" txt_i="6246" txt_f="6279">Green Tea Extract (High Caffeine)</offsets></td><td align="left"><offsets xml_i="11586" xml_f="11625" txt_i="6280" txt_f="6319">40% Polyphenols, 22% EGCG, 40% Caffeine</offsets></td><td align="left"><offsets xml_i="11647" xml_f="11650" txt_i="6320" txt_f="6323">100</offsets></td><td align="left"><offsets xml_i="11672" xml_f="11675" txt_i="6324" txt_f="6327">200</offsets></td></tr><tr><td align="left"><offsets xml_i="11706" xml_f="11714" txt_i="6328" txt_f="6336">Selenium</offsets></td><td align="left"><offsets xml_i="11736" xml_f="11759" txt_i="6337" txt_f="6360">0.5% l-Selenomethionine</offsets></td><td align="left"><offsets xml_i="11781" xml_f="11785" txt_i="6361" txt_f="6365">0.06</offsets></td><td align="left"><offsets xml_i="11807" xml_f="11811" txt_i="6366" txt_f="6370">0.12</offsets></td></tr><tr><td align="left"><offsets xml_i="11842" xml_f="11853" txt_i="6371" txt_f="6382">AlbumaSoy**</offsets></td><td align="left"><offsets xml_i="11875" xml_f="11886" txt_i="6383" txt_f="6394">Soy Albumin</offsets></td><td align="left"><offsets xml_i="11908" xml_f="11910" txt_i="6395" txt_f="6397">50</offsets></td><td align="left"><offsets xml_i="11932" xml_f="11935" txt_i="6398" txt_f="6401">100</offsets></td></tr><tr><td align="left"><offsets xml_i="11966" xml_f="11976" txt_i="6402" txt_f="6412">Vitamin B6</offsets></td><td align="left"><offsets xml_i="11998" xml_f="12022" txt_i="6413" txt_f="6437">pyridoxine hydrochloride</offsets></td><td align="left"><offsets xml_i="12044" xml_f="12046" txt_i="6438" txt_f="6440">50</offsets></td><td align="left"><offsets xml_i="12068" xml_f="12071" txt_i="6441" txt_f="6444">100</offsets></td></tr><tr><td align="left"><offsets xml_i="12102" xml_f="12113" txt_i="6445" txt_f="6456">Vitamin B12</offsets></td><td align="left"><offsets xml_i="12135" xml_f="12149" txt_i="6457" txt_f="6471">cyanocobalamin</offsets></td><td align="left"><offsets xml_i="12171" xml_f="12175" txt_i="6472" txt_f="6476">0.05</offsets></td><td align="left"><offsets xml_i="12197" xml_f="12200" txt_i="6477" txt_f="6480">0.1</offsets></td></tr><tr><td align="left"><offsets xml_i="12231" xml_f="12241" txt_i="6481" txt_f="6491">Folic Acid</offsets></td><td align="left"><offsets xml_i="12263" xml_f="12273" txt_i="6492" txt_f="6502">Folic acid</offsets></td><td align="left"><offsets xml_i="12295" xml_f="12298" txt_i="6503" txt_f="6506">0.4</offsets></td><td align="left"><offsets xml_i="12320" xml_f="12323" txt_i="6507" txt_f="6510">0.8</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="12399" xml_f="12413" txt_i="6512" txt_f="6526">Total Per Unit</offsets></bold></td><td></td><td align="left"><bold><offsets xml_i="12457" xml_f="12463" txt_i="6528" txt_f="6534">104.08</offsets></bold></td><td align="left"><bold><offsets xml_i="12498" xml_f="12505" txt_i="6535" txt_f="6542">265.645</offsets></bold></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="12558" xml_f="12604" txt_i="6543" txt_f="6589">*ChromeMate is a trademark of InterHealth N.I.</offsets></p><p><offsets xml_i="12611" xml_f="12652" txt_i="6590" txt_f="6631">**AlbumaSoy is trademark of Soy Labs, LLC</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><italic><offsets xml_i="12713" xml_f="12722" txt_i="6633" txt_f="6642">In vitro </offsets></italic><offsets xml_i="12731" xml_f="12788" txt_i="6642" txt_f="6699">antioxidant potential of the CORE formulation and CQR-300</offsets></title><p><offsets xml_i="12799" xml_f="12908" txt_i="6700" txt_f="6809">Both CORE and CQR-300 were dissolved in acidified methanol prepared as previously described by Agbor et al. [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="12940" xml_f="12942" txt_i="6809" txt_f="6811">19</offsets></xref><offsets xml_i="12949" xml_f="12959" txt_i="6811" txt_f="6821">] for the </offsets><italic><offsets xml_i="12967" xml_f="12976" txt_i="6821" txt_f="6830">in vitro </offsets></italic><offsets xml_i="12985" xml_f="13232" txt_i="6830" txt_f="7077">antioxidant study. Three methods were used for the determination of antioxidant potential: Folin (polyphenol content), ferric reducing antioxidant power (FRAP, antioxidant power), 1,1-Diphenyl-2-picrilhydrazyl (DPPH, redical scavenging potential).</offsets></p><sec><title><offsets xml_i="13248" xml_f="13266" txt_i="7078" txt_f="7096">Polyphenol content</offsets></title><p><offsets xml_i="13277" xml_f="13537" txt_i="7097" txt_f="7357">The Folin Ciocalteu reagent (Sigma Chemical Co., St Louis, MO, USA) was used to determine the concentration of polyphenol as a measure of antioxidant potential of CORE and CRQ-300. The reagent was diluted 10 times before used as described by Singleton et al. [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="13569" xml_f="13571" txt_i="7357" txt_f="7359">28</offsets></xref><offsets xml_i="13578" xml_f="13643" txt_i="7359" txt_f="7424">]. The absorbance was measured at 750 nm (Genesys Spectronic 20).</offsets></p><p><offsets xml_i="13650" xml_f="13685" txt_i="7425" txt_f="7460">Ferric Reducing Antioxidant Power (</offsets><bold><offsets xml_i="13691" xml_f="13695" txt_i="7460" txt_f="7464">FRAP</offsets></bold><offsets xml_i="13702" xml_f="13761" txt_i="7464" txt_f="7523">) was measured as earlier described by Benzie and Strain. [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="13793" xml_f="13795" txt_i="7523" txt_f="7525">29</offsets></xref><offsets xml_i="13802" xml_f="14070" txt_i="7525" txt_f="7793">]. In brief, 2000 μl of freshly prepared FRAP reagent (10 parts of 300 mM acetate buffer (pH 3.6), 1 part of 10 mM TPTZ (Sigma, in 400 mM HCL), and 1 part of 20 mM ferric chloride). After an initial incubation for 15 minutes at 37°C, the absorbance was read at 593 nm.</offsets></p><p><offsets xml_i="14077" xml_f="14137" txt_i="7794" txt_f="7854">Scavenging potential against 1,1-Diphenyl-2-picrilhydrazyl (</offsets><bold><offsets xml_i="14143" xml_f="14147" txt_i="7854" txt_f="7858">DPPH</offsets></bold><offsets xml_i="14154" xml_f="14582" txt_i="7858" txt_f="8286">) measured the ability of the extracts to scavenge free radicals. 20 μl of extract was introduced into 2 ml methanolic solution of DPPH (0.3 mM) and kept in the dark for 30 minutes. The extract was replaced by methanol for the control, and catechin was used as the standard. The absorbance was read at 517 nm, and the antioxidant content and percentage inhibition of the extract calculated as earlier described by Yen and Duh, [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="14614" xml_f="14616" txt_i="8286" txt_f="8288">30</offsets></xref><offsets xml_i="14623" xml_f="14625" txt_i="8288" txt_f="8290">].</offsets></p><p><offsets xml_i="14632" xml_f="14708" txt_i="8291" txt_f="8367">In all three methods mentioned above, measurements were done in triplicates.</offsets></p></sec></sec><sec><title><italic><offsets xml_i="14744" xml_f="14752" txt_i="8370" txt_f="8378">In vivo </offsets></italic><offsets xml_i="14761" xml_f="14766" txt_i="8378" txt_f="8383">study</offsets></title><sec><title><offsets xml_i="14786" xml_f="14798" txt_i="8384" txt_f="8396">Participants</offsets></title><p><offsets xml_i="14809" xml_f="15841" txt_i="8397" txt_f="9429">A total of 168 overweight, obese, and normal weight participants aged between 19 and 50 years were selected from a group responding to a radio and poster advert. The BMIs of participants ranged from 25.0 to 48.7, and their weights ranged from 70.6 to 142 kg. After physical examination, which included measurement of blood pressure, participants with unusually elevated fasting blood glucose levels, those who were pregnant or lactating, as well as those on any form of weight-reducing medication were excluded from the study. Also excluded were participants who were involved in intense exercise programs, had medical conditions known to affect serum lipids, or had a history of drug or alcohol abuse. A total of 153 participants completed the study, while 15 participants dropped out of the study for personal reasons (7 moved out of town or had to travel during study period; 4 participants thought they had lost enough weight; while 4 participants were on malaria treatment and were excluded before the end of the study period).</offsets></p></sec></sec><sec><title><offsets xml_i="15869" xml_f="15883" txt_i="9432" txt_f="9446">Trial protocol</offsets></title><p><offsets xml_i="15894" xml_f="16076" txt_i="9447" txt_f="9629">The study was double-blind placebo controlled, with the 168 overweight, obese, or normal weight participants of both sexes (between 19 and 50 years) distributed as outlined in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="16108" xml_f="16109" txt_i="9629" txt_f="9630">2</offsets></xref><offsets xml_i="16116" xml_f="16859" txt_i="9630" txt_f="10373">. The participants who were either on their normal diet or on an energy restricted (2100 Kcal/day) diet, received two daily doses in the form of capsules of CORE for 8 weeks, and CQR-300 or placebo for 6 weeks. The capsules were identical in shape, color, and appearance, with neither the participants nor researchers knowing what capsule they received. Side effects were solicited on each weekly visit. Body weight and percentage body fat were determined in 12-hour fasted participants using a Tanita™ scale. Height was measured with a stadiometer to the nearest 0.5 cm. Blood samples were obtained at the start and end of the trial period after a 12-hour overnight fast, into heparinized tubes, for the measurement of LDL oxidation (TBARS) [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="16891" xml_f="16893" txt_i="10373" txt_f="10375">31</offsets></xref><offsets xml_i="16900" xml_f="16924" txt_i="10375" txt_f="10399">] and protein carbonyl [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="16956" xml_f="16958" txt_i="10399" txt_f="10401">32</offsets></xref><offsets xml_i="16965" xml_f="17359" txt_i="10401" txt_f="10795">] content, total cholesterol, triacylglycerol, HDL-cholesterol, LDL-cholesterol, and glucose (cholesterol Infinity, triglyceride Infinity, EZ HDL™ cholesterol, EZ LDL™ cholesterol, Glucose Trinder) from SIGMA Diagnostics. Serotonin was measured using an enzyme immunoassay method (Serotonin EIA kit, BioSource Europe S.A, Belgium), creatinine by a modification of the method of Bartels et al. [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="17391" xml_f="17393" txt_i="10795" txt_f="10797">33</offsets></xref><offsets xml_i="17400" xml_f="17460" txt_i="10797" txt_f="10857">], while MDA was measured by a standard established method [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="17492" xml_f="17494" txt_i="10857" txt_f="10859">34</offsets></xref><offsets xml_i="17501" xml_f="17503" txt_i="10859" txt_f="10861">].</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="17551" xml_f="17558" txt_i="10862" txt_f="10869">Table 2</offsets></label><caption><p><offsets xml_i="17578" xml_f="17750" txt_i="10869" txt_f="11041">Distribution of participants into treatment groups. The number given in parentheses represents the participants whose complete measurements were done over the study period.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="17829" xml_f="17838" txt_i="11042" txt_f="11051">Group No.</offsets></td><td align="left"><offsets xml_i="17860" xml_f="17872" txt_i="11052" txt_f="11064">Participants</offsets></td><td align="left"><offsets xml_i="17894" xml_f="17903" txt_i="11065" txt_f="11074">Treatment</offsets></td><td align="left"><offsets xml_i="17925" xml_f="17944" txt_i="11075" txt_f="11094">No. of Participants</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="17990" xml_f="17991" txt_i="11095" txt_f="11096">1</offsets></td><td align="left"><offsets xml_i="18013" xml_f="18036" txt_i="11097" txt_f="11117">Males/Females BMI&gt;30</offsets></td><td align="left"><offsets xml_i="18058" xml_f="18094" txt_i="11118" txt_f="11154">Placebo 6 weeks (2100 Kcal/day diet)</offsets></td><td align="left"><offsets xml_i="18116" xml_f="18123" txt_i="11155" txt_f="11162">33 (32)</offsets></td></tr><tr><td align="left"><offsets xml_i="18154" xml_f="18155" txt_i="11163" txt_f="11164">2</offsets></td><td align="left"><offsets xml_i="18177" xml_f="18200" txt_i="11165" txt_f="11185">Males/Females BMI&gt;30</offsets></td><td align="left"><offsets xml_i="18222" xml_f="18259" txt_i="11186" txt_f="11223">CORE 8 weeks (no dietary restriction)</offsets></td><td align="left"><offsets xml_i="18281" xml_f="18288" txt_i="11224" txt_f="11231">33 (30)</offsets></td></tr><tr><td align="left"><offsets xml_i="18319" xml_f="18320" txt_i="11232" txt_f="11233">3</offsets></td><td align="left"><offsets xml_i="18342" xml_f="18365" txt_i="11234" txt_f="11254">Males/Females BMI&gt;30</offsets></td><td align="left"><offsets xml_i="18387" xml_f="18420" txt_i="11255" txt_f="11288">CORE 8 weeks (2100 Kcal/day diet)</offsets></td><td align="left"><offsets xml_i="18442" xml_f="18449" txt_i="11289" txt_f="11296">35 (31)</offsets></td></tr><tr><td align="left"><offsets xml_i="18480" xml_f="18481" txt_i="11297" txt_f="11298">4</offsets></td><td align="left"><offsets xml_i="18503" xml_f="18526" txt_i="11299" txt_f="11319">Males/Females BMI&gt;30</offsets></td><td align="left"><offsets xml_i="18548" xml_f="18584" txt_i="11320" txt_f="11356">CQR-300 6 weeks (2100 Kcal/day diet)</offsets></td><td align="left"><offsets xml_i="18606" xml_f="18613" txt_i="11357" txt_f="11364">35 (32)</offsets></td></tr><tr><td align="left"><offsets xml_i="18644" xml_f="18645" txt_i="11365" txt_f="11366">5</offsets></td><td align="left"><offsets xml_i="18667" xml_f="18692" txt_i="11367" txt_f="11392">Males/Females BMI 25–29.9</offsets></td><td align="left"><offsets xml_i="18714" xml_f="18751" txt_i="11393" txt_f="11430">CORE 8 weeks (no dietary restriction)</offsets></td><td align="left"><offsets xml_i="18773" xml_f="18780" txt_i="11431" txt_f="11438">32 (28)</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="18837" xml_f="18857" txt_i="11440" txt_f="11460">Statistical analyses</offsets></title><p><offsets xml_i="18868" xml_f="18920" txt_i="11461" txt_f="11513">Statistical Package for the Social Sciences (SPSS) [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="18952" xml_f="18954" txt_i="11513" txt_f="11515">35</offsets></xref><offsets xml_i="18961" xml_f="19375" txt_i="11515" txt_f="11929">] software was used for all statistical analysis. The data were presented as means ± SD. The statistical difference between samples was assessed by a Student's t-test for normal distribution or the Mann-Whitney test for non-normal distribution, after ANOVA testing of all the groups showed that significant differences existed. Paired Student's t-test was carried out on the start and end values of all the groups.</offsets></p></sec></sec><sec><title><offsets xml_i="19403" xml_f="19410" txt_i="11932" txt_f="11939">Results</offsets></title><sec><title><italic><offsets xml_i="19438" xml_f="19447" txt_i="11940" txt_f="11949">In vitro </offsets></italic><offsets xml_i="19456" xml_f="19498" txt_i="11949" txt_f="11991">fantioxidant potential of CORE and CQR-300</offsets></title><p><offsets xml_i="19509" xml_f="19513" txt_i="11992" txt_f="11996">The </offsets><italic><offsets xml_i="19521" xml_f="19530" txt_i="11996" txt_f="12005">in vitro </offsets></italic><offsets xml_i="19539" xml_f="19716" txt_i="12005" txt_f="12179">antioxidant capacity of CORE was significantly (p &lt; 0.01) higher than that of CQR-300 irrespective of the method of analysis used. Considering the composition of CORE (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="19748" xml_f="19749" txt_i="12179" txt_f="12180">1</offsets></xref><offsets xml_i="19756" xml_f="19835" txt_i="12180" txt_f="12259">), it is likely that the other components present act synergistically with the </offsets><italic><offsets xml_i="19843" xml_f="19865" txt_i="12259" txt_f="12281">Cissus quadrangularis </offsets></italic><offsets xml_i="19874" xml_f="19897" txt_i="12281" txt_f="12304">extract present (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="19929" xml_f="19930" txt_i="12304" txt_f="12305">3</offsets></xref><offsets xml_i="19937" xml_f="19939" txt_i="12305" txt_f="12307">).</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="19987" xml_f="19994" txt_i="12308" txt_f="12315">Table 3</offsets></label><caption><p><italic><offsets xml_i="20022" xml_f="20031" txt_i="12315" txt_f="12324">In vitro </offsets></italic><offsets xml_i="20040" xml_f="20162" txt_i="12324" txt_f="12446">antioxidant capacity of the CORE and CQR-300 (mg of catechin equivalent/gram dry weight) by FRAP, Folin, and DPPH methods.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><offsets xml_i="20250" xml_f="20273" txt_i="12448" txt_f="12471">FRAP Antioxidant (mg/g)</offsets></td><td align="left"><offsets xml_i="20295" xml_f="20324" txt_i="12472" txt_f="12501">Folin Total Polyphenol (mg/g)</offsets></td><td align="left"><offsets xml_i="20346" xml_f="20369" txt_i="12502" txt_f="12525">DPPH Antioxidant (mg/g)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="20415" xml_f="20419" txt_i="12526" txt_f="12530">CORE</offsets></td><td align="left"><offsets xml_i="20441" xml_f="20453" txt_i="12531" txt_f="12543">22.67 ± 4.58</offsets></td><td align="left"><offsets xml_i="20475" xml_f="20487" txt_i="12544" txt_f="12556">56.70 ± 6.12</offsets></td><td align="left"><offsets xml_i="20509" xml_f="20520" txt_i="12557" txt_f="12568">8.46 ± 1.30</offsets></td></tr><tr><td align="left"><offsets xml_i="20551" xml_f="20558" txt_i="12569" txt_f="12576">CQR-300</offsets></td><td align="left"><offsets xml_i="20580" xml_f="20593" txt_i="12577" txt_f="12590">15.85 ± 3.08*</offsets></td><td align="left"><offsets xml_i="20615" xml_f="20628" txt_i="12591" txt_f="12604">42.33 ± 3.21*</offsets></td><td align="left"><offsets xml_i="20650" xml_f="20662" txt_i="12605" txt_f="12617">5.97 ± 0.66*</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="20708" xml_f="20772" txt_i="12618" txt_f="12679">*p &lt; 0.01 compared to the cissus formulation for each method.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="20810" xml_f="20816" txt_i="12680" txt_f="12686">Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="20848" xml_f="20849" txt_i="12686" txt_f="12687">4</offsets></xref><offsets xml_i="20856" xml_f="21180" txt_i="12687" txt_f="13008"> presents the effect of CORE and CQR-300 on the oxidative stress parameter (TBARS and carbonyls). CORE was more effective in reducing oxidative stress than CQR-300, the reduction being more obvious in the diet-restricted group. It significantly (p &lt; 0.01) reduced the formation of TBARS and carbonyls compared to CQR-300.</offsets></p><table-wrap position="float" id="T4"><label><offsets xml_i="21228" xml_f="21235" txt_i="13009" txt_f="13016">Table 4</offsets></label><caption><p><offsets xml_i="21255" xml_f="21344" txt_i="13016" txt_f="13105">The effect of the CORE and CQR-300 extracts on the concentrations of TBARS and carbonyls.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><offsets xml_i="21444" xml_f="21451" txt_i="13107" txt_f="13114">Group 1</offsets><break></break><offsets xml_i="21466" xml_f="21475" txt_i="13114" txt_f="13120">BMI&gt;30</offsets><break></break><offsets xml_i="21490" xml_f="21497" txt_i="13120" txt_f="13127">Placebo</offsets><break></break><offsets xml_i="21512" xml_f="21532" txt_i="13127" txt_f="13147">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="21566" xml_f="21573" txt_i="13148" txt_f="13155">Group 2</offsets><break></break><offsets xml_i="21588" xml_f="21597" txt_i="13155" txt_f="13161">BMI&gt;30</offsets><break></break><offsets xml_i="21612" xml_f="21616" txt_i="13161" txt_f="13165">CORE</offsets><break></break><offsets xml_i="21631" xml_f="21655" txt_i="13165" txt_f="13189">(no dietary restriction)</offsets></td><td align="left" colspan="2"><offsets xml_i="21689" xml_f="21696" txt_i="13190" txt_f="13197">Group 3</offsets><break></break><offsets xml_i="21711" xml_f="21720" txt_i="13197" txt_f="13203">BMI&gt;30</offsets><break></break><offsets xml_i="21735" xml_f="21739" txt_i="13203" txt_f="13207">CORE</offsets><break></break><offsets xml_i="21754" xml_f="21774" txt_i="13207" txt_f="13227">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="21808" xml_f="21815" txt_i="13228" txt_f="13235">Group 4</offsets><break></break><offsets xml_i="21830" xml_f="21839" txt_i="13235" txt_f="13241">BMI&gt;30</offsets><break></break><offsets xml_i="21854" xml_f="21861" txt_i="13241" txt_f="13248">CQR-300</offsets><break></break><offsets xml_i="21876" xml_f="21896" txt_i="13248" txt_f="13268">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="21930" xml_f="21937" txt_i="13269" txt_f="13276">Group 5</offsets><break></break><offsets xml_i="21952" xml_f="21963" txt_i="13276" txt_f="13287">BMI 25–29.9</offsets><break></break><offsets xml_i="21978" xml_f="21982" txt_i="13287" txt_f="13291">CORE</offsets><break></break><offsets xml_i="21997" xml_f="22021" txt_i="13291" txt_f="13315">(no dietary restriction)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="22067" xml_f="22079" txt_i="13316" txt_f="13328">Time (weeks)</offsets></td><td align="left"><offsets xml_i="22101" xml_f="22106" txt_i="13329" txt_f="13334">T = 0</offsets></td><td align="left"><offsets xml_i="22128" xml_f="22133" txt_i="13335" txt_f="13340">T = 6</offsets></td><td align="left"><offsets xml_i="22155" xml_f="22160" txt_i="13341" txt_f="13346">T = 0</offsets></td><td align="left"><offsets xml_i="22182" xml_f="22187" txt_i="13347" txt_f="13352">T = 8</offsets></td><td align="left"><offsets xml_i="22209" xml_f="22214" txt_i="13353" txt_f="13358">T = 0</offsets></td><td align="left"><offsets xml_i="22236" xml_f="22241" txt_i="13359" txt_f="13364">T = 8</offsets></td><td align="left"><offsets xml_i="22263" xml_f="22268" txt_i="13365" txt_f="13370">T = 0</offsets></td><td align="left"><offsets xml_i="22290" xml_f="22295" txt_i="13371" txt_f="13376">T = 6</offsets></td><td align="left"><offsets xml_i="22317" xml_f="22322" txt_i="13377" txt_f="13382">T = 0</offsets></td><td align="left"><offsets xml_i="22344" xml_f="22349" txt_i="13383" txt_f="13388">T = 8</offsets></td></tr><tr><td align="left"><offsets xml_i="22380" xml_f="22394" txt_i="13389" txt_f="13403">TBARS (umol/L)</offsets></td><td align="left"><offsets xml_i="22416" xml_f="22427" txt_i="13404" txt_f="13415">1.42 ± 0.51</offsets></td><td align="left"><offsets xml_i="22449" xml_f="22460" txt_i="13416" txt_f="13427">1.60 ± 0.38</offsets></td><td align="left"><offsets xml_i="22482" xml_f="22493" txt_i="13428" txt_f="13439">1.66 ± 0.56</offsets></td><td align="left"><offsets xml_i="22515" xml_f="22528" txt_i="13440" txt_f="13453">0.87 ± 0.53**</offsets></td><td align="left"><offsets xml_i="22550" xml_f="22561" txt_i="13454" txt_f="13465">1.78 ± 0.38</offsets></td><td align="left"><offsets xml_i="22583" xml_f="22596" txt_i="13466" txt_f="13479">0.72 ± 0.35**</offsets><sup><offsets xml_i="22601" xml_f="22602" txt_i="13479" txt_f="13480">†</offsets></sup></td><td align="left"><offsets xml_i="22630" xml_f="22641" txt_i="13481" txt_f="13492">1.84 ± 0.51</offsets></td><td align="left"><offsets xml_i="22663" xml_f="22676" txt_i="13493" txt_f="13506">0.98 ± 0.18**</offsets></td><td align="left"><offsets xml_i="22698" xml_f="22709" txt_i="13507" txt_f="13518">1.06 ± 0.24</offsets></td><td align="left"><offsets xml_i="22731" xml_f="22744" txt_i="13519" txt_f="13532">0.66 ± 0.13**</offsets><sup><offsets xml_i="22749" xml_f="22750" txt_i="13532" txt_f="13533">†</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="22787" xml_f="22814" txt_i="13534" txt_f="13561">Carbonyls (nmol/mg protein)</offsets></td><td align="left"><offsets xml_i="22836" xml_f="22847" txt_i="13562" txt_f="13573">1.95 ± 0.73</offsets></td><td align="left"><offsets xml_i="22869" xml_f="22880" txt_i="13574" txt_f="13585">2.09 ± 0.68</offsets></td><td align="left"><offsets xml_i="22902" xml_f="22913" txt_i="13586" txt_f="13597">2.03 ± 0.39</offsets></td><td align="left"><offsets xml_i="22935" xml_f="22948" txt_i="13598" txt_f="13611">0.98 ± 0.39**</offsets></td><td align="left"><offsets xml_i="22970" xml_f="22981" txt_i="13612" txt_f="13623">1.96 ± 0.40</offsets></td><td align="left"><offsets xml_i="23003" xml_f="23016" txt_i="13624" txt_f="13637">0.84 ± 0.27**</offsets><sup><offsets xml_i="23021" xml_f="23022" txt_i="13637" txt_f="13638">†</offsets></sup></td><td align="left"><offsets xml_i="23050" xml_f="23061" txt_i="13639" txt_f="13650">2.06 ± 0.28</offsets></td><td align="left"><offsets xml_i="23083" xml_f="23096" txt_i="13651" txt_f="13664">1.10 ± 0.34**</offsets></td><td align="left"><offsets xml_i="23118" xml_f="23129" txt_i="13665" txt_f="13676">0.94 ± 0.20</offsets></td><td align="left"><offsets xml_i="23151" xml_f="23164" txt_i="13677" txt_f="13690">0.77 ± 0.36**</offsets><sup><offsets xml_i="23169" xml_f="23170" txt_i="13690" txt_f="13691">†</offsets></sup></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="23222" xml_f="23256" txt_i="13692" txt_f="13723">**p &lt; 0.001 compared to T = 0; </offsets><sup><offsets xml_i="23261" xml_f="23262" txt_i="13723" txt_f="13724">†</offsets></sup><offsets xml_i="23268" xml_f="23310" txt_i="13724" txt_f="13763">p &lt; 0.01 compared to CQR-300 (Group 4).</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="23363" xml_f="23404" txt_i="13765" txt_f="13806">Effect of CORE and CQR-300 on body weight</offsets></title><p><offsets xml_i="23415" xml_f="23573" txt_i="13807" txt_f="13962">Obese participants, who received CQR-300 (300 mg daily), had significantly (p &lt; 0.05) greater reduction in body weight compared to those on placebo (Table </offsets><xref ref-type="table" rid="T5"><offsets xml_i="23605" xml_f="23606" txt_i="13962" txt_f="13963">5</offsets></xref><offsets xml_i="23613" xml_f="23948" txt_i="13963" txt_f="14295">). This reduction in body weight corresponded to a 5.4 % reduction in BMI. CORE had a more significant (p &lt; 0.01) effect (8.5% reduction for participants on an energy restricted diet) on the weight of participants compared to CQR-300. There was no significant net change in weight in participants on placebo during the study period.</offsets></p><table-wrap position="float" id="T5"><label><offsets xml_i="23996" xml_f="24003" txt_i="14296" txt_f="14303">Table 5</offsets></label><caption><p><offsets xml_i="24023" xml_f="24085" txt_i="14303" txt_f="14365">Effect oftheCORE and CQR-300 on body weight, BMI, and Body fat</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><offsets xml_i="24185" xml_f="24192" txt_i="14367" txt_f="14374">Group 1</offsets><break></break><offsets xml_i="24207" xml_f="24216" txt_i="14374" txt_f="14380">BMI&gt;30</offsets><break></break><offsets xml_i="24231" xml_f="24238" txt_i="14380" txt_f="14387">Placebo</offsets><break></break><offsets xml_i="24253" xml_f="24273" txt_i="14387" txt_f="14407">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="24307" xml_f="24314" txt_i="14408" txt_f="14415">Group 2</offsets><break></break><offsets xml_i="24329" xml_f="24338" txt_i="14415" txt_f="14421">BMI&gt;30</offsets><break></break><offsets xml_i="24353" xml_f="24357" txt_i="14421" txt_f="14425">CORE</offsets><break></break><offsets xml_i="24372" xml_f="24396" txt_i="14425" txt_f="14449">(no dietary restriction)</offsets></td><td align="left" colspan="2"><offsets xml_i="24430" xml_f="24437" txt_i="14450" txt_f="14457">Group 3</offsets><break></break><offsets xml_i="24452" xml_f="24461" txt_i="14457" txt_f="14463">BMI&gt;30</offsets><break></break><offsets xml_i="24476" xml_f="24480" txt_i="14463" txt_f="14467">CORE</offsets><break></break><offsets xml_i="24495" xml_f="24515" txt_i="14467" txt_f="14487">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="24549" xml_f="24556" txt_i="14488" txt_f="14495">Group 4</offsets><break></break><offsets xml_i="24571" xml_f="24580" txt_i="14495" txt_f="14501">BMI&gt;30</offsets><break></break><offsets xml_i="24595" xml_f="24602" txt_i="14501" txt_f="14508">CQR-300</offsets><break></break><offsets xml_i="24617" xml_f="24637" txt_i="14508" txt_f="14528">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="24671" xml_f="24678" txt_i="14529" txt_f="14536">Group 5</offsets><break></break><offsets xml_i="24693" xml_f="24704" txt_i="14536" txt_f="14547">BMI 24–29.9</offsets><break></break><offsets xml_i="24719" xml_f="24723" txt_i="14547" txt_f="14551">CORE</offsets><break></break><offsets xml_i="24738" xml_f="24762" txt_i="14551" txt_f="14575">(no dietary restriction)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="24808" xml_f="24820" txt_i="14576" txt_f="14588">Time (weeks)</offsets></td><td align="left"><offsets xml_i="24842" xml_f="24847" txt_i="14589" txt_f="14594">T = 0</offsets></td><td align="left"><offsets xml_i="24869" xml_f="24874" txt_i="14595" txt_f="14600">T = 6</offsets></td><td align="left"><offsets xml_i="24896" xml_f="24901" txt_i="14601" txt_f="14606">T = 0</offsets></td><td align="left"><offsets xml_i="24923" xml_f="24928" txt_i="14607" txt_f="14612">T = 8</offsets></td><td align="left"><offsets xml_i="24950" xml_f="24955" txt_i="14613" txt_f="14618">T = 0</offsets></td><td align="left"><offsets xml_i="24977" xml_f="24982" txt_i="14619" txt_f="14624">T = 8</offsets></td><td align="left"><offsets xml_i="25004" xml_f="25009" txt_i="14625" txt_f="14630">T = 0</offsets></td><td align="left"><offsets xml_i="25031" xml_f="25036" txt_i="14631" txt_f="14636">T = 6</offsets></td><td align="left"><offsets xml_i="25058" xml_f="25063" txt_i="14637" txt_f="14642">T = 0</offsets></td><td align="left"><offsets xml_i="25085" xml_f="25090" txt_i="14643" txt_f="14648">T = 8</offsets></td></tr><tr><td align="left"><offsets xml_i="25121" xml_f="25132" txt_i="14649" txt_f="14660">Weight (kg)</offsets></td><td align="left"><offsets xml_i="25154" xml_f="25165" txt_i="14661" txt_f="14672">112.4 ± 2.6</offsets></td><td align="left"><offsets xml_i="25187" xml_f="25204" txt_i="14673" txt_f="14690">113.6 ± 2.0 (1.1)</offsets></td><td align="left"><offsets xml_i="25226" xml_f="25237" txt_i="14691" txt_f="14702">95.8 ± 11.8</offsets></td><td align="left"><offsets xml_i="25259" xml_f="25276" txt_i="14703" txt_f="14720">89.2 ± 9.2 (6.9)*</offsets></td><td align="left"><offsets xml_i="25298" xml_f="25309" txt_i="14721" txt_f="14732">95.3 ± 14.6</offsets></td><td align="left"><offsets xml_i="25331" xml_f="25349" txt_i="14733" txt_f="14751">87.2 ± 8.9 (8.5)**</offsets><sup><offsets xml_i="25354" xml_f="25355" txt_i="14751" txt_f="14752">†</offsets></sup></td><td align="left"><offsets xml_i="25383" xml_f="25394" txt_i="14753" txt_f="14764">118.6 ± 3.8</offsets></td><td align="left"><offsets xml_i="25416" xml_f="25434" txt_i="14765" txt_f="14783">113.8 ± 2.5 (4.0)*</offsets></td><td align="left"><offsets xml_i="25456" xml_f="25466" txt_i="14784" txt_f="14794">76.3 ± 6.8</offsets></td><td align="left"><offsets xml_i="25488" xml_f="25505" txt_i="14795" txt_f="14812">72.5 ± 4.7 (5.0)*</offsets></td></tr><tr><td align="left"><offsets xml_i="25536" xml_f="25545" txt_i="14813" txt_f="14822">BMI (kg/m</offsets><sup><offsets xml_i="25550" xml_f="25551" txt_i="14822" txt_f="14823">2</offsets></sup><offsets xml_i="25557" xml_f="25558" txt_i="14823" txt_f="14824">)</offsets></td><td align="left"><offsets xml_i="25580" xml_f="25590" txt_i="14825" txt_f="14835">38.1 ± 1.1</offsets></td><td align="left"><offsets xml_i="25612" xml_f="25622" txt_i="14836" txt_f="14846">38.0 ± 0.9</offsets></td><td align="left"><offsets xml_i="25644" xml_f="25654" txt_i="14847" txt_f="14857">37.7 ± 6.3</offsets></td><td align="left"><offsets xml_i="25676" xml_f="25686" txt_i="14858" txt_f="14868">34.6 ± 8.6</offsets></td><td align="left"><offsets xml_i="25708" xml_f="25718" txt_i="14869" txt_f="14879">37.5 ± 4.7</offsets></td><td align="left"><offsets xml_i="25740" xml_f="25750" txt_i="14880" txt_f="14890">33.8 ± 6.9</offsets></td><td align="left"><offsets xml_i="25772" xml_f="25782" txt_i="14891" txt_f="14901">38.8 ± 1.0</offsets></td><td align="left"><offsets xml_i="25804" xml_f="25814" txt_i="14902" txt_f="14912">36.7 ± 3.4</offsets></td><td align="left"><offsets xml_i="25836" xml_f="25846" txt_i="14913" txt_f="14923">27.3 ± 2.5</offsets></td><td align="left"><offsets xml_i="25868" xml_f="25878" txt_i="14924" txt_f="14934">26.3 ± 3.0</offsets></td></tr><tr><td align="left"><offsets xml_i="25909" xml_f="25921" txt_i="14935" txt_f="14947">Body fat (%)</offsets></td><td align="left"><offsets xml_i="25943" xml_f="25953" txt_i="14948" txt_f="14958">43.6 ± 1.6</offsets></td><td align="left"><offsets xml_i="25975" xml_f="25985" txt_i="14959" txt_f="14969">42.8 ± 2.1</offsets></td><td align="left"><offsets xml_i="26007" xml_f="26017" txt_i="14970" txt_f="14980">46.5 ± 3.1</offsets></td><td align="left"><offsets xml_i="26039" xml_f="26049" txt_i="14981" txt_f="14991">43.7 ± 2.4</offsets></td><td align="left"><offsets xml_i="26071" xml_f="26081" txt_i="14992" txt_f="15002">48.1 ± 4.4</offsets></td><td align="left"><offsets xml_i="26103" xml_f="26113" txt_i="15003" txt_f="15013">44.3 ± 2.1</offsets></td><td align="left"><offsets xml_i="26135" xml_f="26145" txt_i="15014" txt_f="15024">44.3 ± 5.4</offsets></td><td align="left"><offsets xml_i="26167" xml_f="26177" txt_i="15025" txt_f="15035">42.1 ± 3.6</offsets></td><td align="left"><offsets xml_i="26199" xml_f="26209" txt_i="15036" txt_f="15046">35.9 ± 2.2</offsets></td><td align="left"><offsets xml_i="26231" xml_f="26241" txt_i="15047" txt_f="15057">34.2 ± 3.0</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="26287" xml_f="26309" txt_i="15058" txt_f="15080">Values are means ± SE.</offsets></p><p><offsets xml_i="26316" xml_f="26365" txt_i="15081" txt_f="15124">*p &lt; 0.05, **p &lt; 0.01, compared to placebo,</offsets><sup><offsets xml_i="26370" xml_f="26371" txt_i="15124" txt_f="15125">†</offsets></sup><offsets xml_i="26377" xml_f="26453" txt_i="15125" txt_f="15198">p &lt; 0.01 compared to CQR-300 (Group 4), () = percentage change in weight.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="26491" xml_f="26497" txt_i="15199" txt_f="15205">Table </offsets><xref ref-type="table" rid="T6"><offsets xml_i="26529" xml_f="26530" txt_i="15205" txt_f="15206">6</offsets></xref><offsets xml_i="26537" xml_f="27234" txt_i="15206" txt_f="15903"> presents the effect of CORE and CQR-300 on blood lipids and fasting blood glucose levels. For participants on a restricted diet, six weeks use of CQR-300 reduced plasma total cholesterol by 18.0%, LDL-cholesterol by 29.0%, triacylglycerol by 21.7%, and fasting blood glucose by 14.6%. This treatment also increased the concentration of HDL-cholesterol by 21.1%. On the other hand, CORE (group 3) reduced the concentration of plasma total cholesterol by 26.0%, LDL-cholesterol by 32.4%, triacylglycerol 28.0%, and fasting blood sugar 16.1%. The CORE formulation also increased HDL cholesterol by 43.0%. The above mentioned changes were less obvious in participants whose diets were not restricted.</offsets></p><table-wrap position="float" id="T6"><label><offsets xml_i="27282" xml_f="27289" txt_i="15904" txt_f="15911">Table 6</offsets></label><caption><p><offsets xml_i="27309" xml_f="27381" txt_i="15911" txt_f="15983">Effect of the CORE and CQR-300 on blood lipids and fasting blood glucose</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><offsets xml_i="27481" xml_f="27488" txt_i="15985" txt_f="15992">Group 1</offsets><break></break><offsets xml_i="27503" xml_f="27512" txt_i="15992" txt_f="15998">BMI&gt;30</offsets><break></break><offsets xml_i="27527" xml_f="27534" txt_i="15998" txt_f="16005">Placebo</offsets><break></break><offsets xml_i="27549" xml_f="27569" txt_i="16005" txt_f="16025">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="27603" xml_f="27610" txt_i="16026" txt_f="16033">Group 2</offsets><break></break><offsets xml_i="27625" xml_f="27634" txt_i="16033" txt_f="16039">BMI&gt;30</offsets><break></break><offsets xml_i="27649" xml_f="27653" txt_i="16039" txt_f="16043">CORE</offsets><break></break><offsets xml_i="27668" xml_f="27692" txt_i="16043" txt_f="16067">(no dietary restriction)</offsets></td><td align="left" colspan="2"><offsets xml_i="27726" xml_f="27733" txt_i="16068" txt_f="16075">Group 3</offsets><break></break><offsets xml_i="27748" xml_f="27757" txt_i="16075" txt_f="16081">BMI&gt;30</offsets><break></break><offsets xml_i="27772" xml_f="27776" txt_i="16081" txt_f="16085">CORE</offsets><break></break><offsets xml_i="27791" xml_f="27811" txt_i="16085" txt_f="16105">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="27845" xml_f="27852" txt_i="16106" txt_f="16113">Group 4</offsets><break></break><offsets xml_i="27867" xml_f="27876" txt_i="16113" txt_f="16119">BMI&gt;30</offsets><break></break><offsets xml_i="27891" xml_f="27898" txt_i="16119" txt_f="16126">CQR-300</offsets><break></break><offsets xml_i="27913" xml_f="27933" txt_i="16126" txt_f="16146">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="27967" xml_f="27974" txt_i="16147" txt_f="16154">Group 5</offsets><break></break><offsets xml_i="27989" xml_f="28000" txt_i="16154" txt_f="16165">BMI 24–29.9</offsets><break></break><offsets xml_i="28015" xml_f="28019" txt_i="16165" txt_f="16169">CORE</offsets><break></break><offsets xml_i="28034" xml_f="28058" txt_i="16169" txt_f="16193">(no dietary restriction)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="28104" xml_f="28116" txt_i="16194" txt_f="16206">Time (weeks)</offsets></td><td align="left"><offsets xml_i="28138" xml_f="28143" txt_i="16207" txt_f="16212">T = 0</offsets></td><td align="left"><offsets xml_i="28165" xml_f="28170" txt_i="16213" txt_f="16218">T = 6</offsets></td><td align="left"><offsets xml_i="28192" xml_f="28197" txt_i="16219" txt_f="16224">T = 0</offsets></td><td align="left"><offsets xml_i="28219" xml_f="28224" txt_i="16225" txt_f="16230">T = 8</offsets></td><td align="left"><offsets xml_i="28246" xml_f="28251" txt_i="16231" txt_f="16236">T = 0</offsets></td><td align="left"><offsets xml_i="28273" xml_f="28278" txt_i="16237" txt_f="16242">T = 8</offsets></td><td align="left"><offsets xml_i="28300" xml_f="28305" txt_i="16243" txt_f="16248">T = 0</offsets></td><td align="left"><offsets xml_i="28327" xml_f="28332" txt_i="16249" txt_f="16254">T = 6</offsets></td><td align="left"><offsets xml_i="28354" xml_f="28359" txt_i="16255" txt_f="16260">T = 0</offsets></td><td align="left"><offsets xml_i="28381" xml_f="28386" txt_i="16261" txt_f="16266">T = 8</offsets></td></tr><tr><td align="left"><offsets xml_i="28417" xml_f="28442" txt_i="16267" txt_f="16292">Total Cholesterol (mg/dL)</offsets></td><td align="left"><offsets xml_i="28464" xml_f="28475" txt_i="16293" txt_f="16304">136.3 ± 9.0</offsets></td><td align="left"><offsets xml_i="28497" xml_f="28509" txt_i="16305" txt_f="16317">138.3 ± 11.1</offsets></td><td align="left"><offsets xml_i="28531" xml_f="28543" txt_i="16318" txt_f="16330">159.1 ± 14.6</offsets></td><td align="left"><offsets xml_i="28565" xml_f="28577" txt_i="16331" txt_f="16343">116.2 ± 9.7*</offsets></td><td align="left"><offsets xml_i="28599" xml_f="28611" txt_i="16344" txt_f="16356">171.0 ± 15.9</offsets></td><td align="left"><offsets xml_i="28633" xml_f="28646" txt_i="16357" txt_f="16370">126.5 ± 7.9 *</offsets><sup><offsets xml_i="28651" xml_f="28652" txt_i="16370" txt_f="16371">†</offsets></sup></td><td align="left"><offsets xml_i="28680" xml_f="28692" txt_i="16372" txt_f="16384">138.3 ± 13.8</offsets></td><td align="left"><offsets xml_i="28714" xml_f="28726" txt_i="16385" txt_f="16397">113.4 ± 4.5*</offsets></td><td align="left"><offsets xml_i="28748" xml_f="28759" txt_i="16398" txt_f="16409">152.6 ± 8.8</offsets></td><td align="left"><offsets xml_i="28781" xml_f="28793" txt_i="16410" txt_f="16422">123.0 ± 4.7*</offsets></td></tr><tr><td align="left"><offsets xml_i="28824" xml_f="28847" txt_i="16423" txt_f="16446">LDL-cholesterol (mg/dL)</offsets></td><td align="left"><offsets xml_i="28869" xml_f="28879" txt_i="16447" txt_f="16457">88.4 ± 5.9</offsets></td><td align="left"><offsets xml_i="28901" xml_f="28911" txt_i="16458" txt_f="16468">88.2 ± 5.9</offsets></td><td align="left"><offsets xml_i="28933" xml_f="28943" txt_i="16469" txt_f="16479">99.8 ± 6.5</offsets></td><td align="left"><offsets xml_i="28965" xml_f="28975" txt_i="16480" txt_f="16490">81.4 ± 1.7</offsets></td><td align="left"><offsets xml_i="28997" xml_f="29008" txt_i="16491" txt_f="16502">116.6 ± 5.4</offsets></td><td align="left"><offsets xml_i="29030" xml_f="29040" txt_i="16503" txt_f="16513">78.8 ± 3.3</offsets></td><td align="left"><offsets xml_i="29062" xml_f="29072" txt_i="16514" txt_f="16524">92.7 ± 7.0</offsets></td><td align="left"><offsets xml_i="29094" xml_f="29104" txt_i="16525" txt_f="16535">65.8 ± 3.4</offsets></td><td align="left"><offsets xml_i="29126" xml_f="29137" txt_i="16536" txt_f="16547">101.6 ± 1.9</offsets></td><td align="left"><offsets xml_i="29159" xml_f="29169" txt_i="16548" txt_f="16558">74.8 ± 0.9</offsets></td></tr><tr><td align="left"><offsets xml_i="29200" xml_f="29223" txt_i="16559" txt_f="16582">HDL-cholesterol (mg/dL)</offsets></td><td align="left"><offsets xml_i="29245" xml_f="29255" txt_i="16583" txt_f="16593">27.3 ± 2.2</offsets></td><td align="left"><offsets xml_i="29277" xml_f="29287" txt_i="16594" txt_f="16604">25.8 ± 3.1</offsets></td><td align="left"><offsets xml_i="29309" xml_f="29319" txt_i="16605" txt_f="16615">36.6 ± 4.7</offsets></td><td align="left"><offsets xml_i="29341" xml_f="29352" txt_i="16616" txt_f="16627">55.1 ± 6.4*</offsets></td><td align="left"><offsets xml_i="29374" xml_f="29385" txt_i="16628" txt_f="16639">38.6 ± 10.5</offsets></td><td align="left"><offsets xml_i="29407" xml_f="29418" txt_i="16640" txt_f="16651">55.2 ± 8.6*</offsets><sup><offsets xml_i="29423" xml_f="29424" txt_i="16651" txt_f="16652">†</offsets></sup></td><td align="left"><offsets xml_i="29452" xml_f="29462" txt_i="16653" txt_f="16663">25.6 ± 4.8</offsets></td><td align="left"><offsets xml_i="29484" xml_f="29494" txt_i="16664" txt_f="16674">31.0 ± 3.9</offsets></td><td align="left"><offsets xml_i="29516" xml_f="29526" txt_i="16675" txt_f="16685">44.4 ± 7.7</offsets></td><td align="left"><offsets xml_i="29548" xml_f="29558" txt_i="16686" txt_f="16696">52.0 ± 8.1</offsets></td></tr><tr><td align="left"><offsets xml_i="29589" xml_f="29612" txt_i="16697" txt_f="16720">Triacylglycerol (mg/dL)</offsets></td><td align="left"><offsets xml_i="29634" xml_f="29644" txt_i="16721" txt_f="16731">93.6 ± 4.8</offsets></td><td align="left"><offsets xml_i="29666" xml_f="29677" txt_i="16732" txt_f="16743">90.5 ± 10.4</offsets></td><td align="left"><offsets xml_i="29699" xml_f="29711" txt_i="16744" txt_f="16756">156.0 ± 16.8</offsets></td><td align="left"><offsets xml_i="29733" xml_f="29743" txt_i="16757" txt_f="16767">95.6 ± 8.1</offsets></td><td align="left"><offsets xml_i="29765" xml_f="29777" txt_i="16768" txt_f="16780">144.9 ± 43.3</offsets></td><td align="left"><offsets xml_i="29799" xml_f="29812" txt_i="16781" txt_f="16794">104.3 ± 26.2*</offsets><sup><offsets xml_i="29817" xml_f="29818" txt_i="16794" txt_f="16795">†</offsets></sup></td><td align="left"><offsets xml_i="29846" xml_f="29856" txt_i="16796" txt_f="16806">93.8 ± 9.7</offsets></td><td align="left"><offsets xml_i="29878" xml_f="29891" txt_i="16807" txt_f="16820">73.4 ± 6.0***</offsets></td><td align="left"><offsets xml_i="29913" xml_f="29924" txt_i="16821" txt_f="16832">117.4 ± 9.8</offsets></td><td align="left"><offsets xml_i="29946" xml_f="29957" txt_i="16833" txt_f="16844">99.8 ± 11.2</offsets></td></tr><tr><td align="left"><offsets xml_i="29988" xml_f="30017" txt_i="16845" txt_f="16874">Fasting Blood glucose (mg/dL)</offsets></td><td align="left"><offsets xml_i="30039" xml_f="30049" txt_i="16875" txt_f="16885">93.6 ± 7.2</offsets></td><td align="left"><offsets xml_i="30071" xml_f="30082" txt_i="16886" txt_f="16897">89.4 ± 10.1</offsets></td><td align="left"><offsets xml_i="30104" xml_f="30115" txt_i="16898" txt_f="16909">101.3 ± 8.6</offsets></td><td align="left"><offsets xml_i="30137" xml_f="30148" txt_i="16910" txt_f="16921">87.7 ± 10.0</offsets></td><td align="left"><offsets xml_i="30170" xml_f="30181" txt_i="16922" txt_f="16933">102.4 ± 1.8</offsets></td><td align="left"><offsets xml_i="30203" xml_f="30213" txt_i="16934" txt_f="16944">85.9 ± 5.2</offsets></td><td align="left"><offsets xml_i="30235" xml_f="30245" txt_i="16945" txt_f="16955">91.8 ± 6.9</offsets></td><td align="left"><offsets xml_i="30267" xml_f="30278" txt_i="16956" txt_f="16967">78.4 ± 11.2</offsets></td><td align="left"><offsets xml_i="30300" xml_f="30311" txt_i="16968" txt_f="16979">93.3 ± 10.2</offsets></td><td align="left"><offsets xml_i="30333" xml_f="30343" txt_i="16980" txt_f="16990">82.7 ± 7.2</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="30389" xml_f="30554" txt_i="16991" txt_f="17147">Values are means ± SE, comparing starting point to end point, significant differences were at *p &lt; 0.05, **p &lt; 0.01 and ***p &lt; 0.001 for the same treatment.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="30592" xml_f="30711" txt_i="17148" txt_f="17267">The effect of CORE and CQR-300 on malondialdehyde (MDA), serum serotonin, and creatinine levels are presented in Table </offsets><xref ref-type="table" rid="T7"><offsets xml_i="30743" xml_f="30744" txt_i="17267" txt_f="17268">7</offsets></xref><offsets xml_i="30751" xml_f="31302" txt_i="17268" txt_f="17810">. CQR-300 significantly (p &lt; 0.05) reduced the concentration of plasma MDA. This effect was accompanied by a slight increase in the urinary concentration of MDA though not significant. CQR-300 also significantly (p &lt; 0.05) increased the concentration of plasma 5-HT by 53.3% and plasma creatinine levels by 23.5%. An increase in 5-HT of 17.0% was also observed in the placebo group, while CORE (group 3) showed a significant increase of 39.1%. As such results for 5-HT and creatinine were significantly (p &lt; 0.05) lower for CORE than CQR-300.</offsets></p><table-wrap position="float" id="T7"><label><offsets xml_i="31350" xml_f="31357" txt_i="17811" txt_f="17818">Table 7</offsets></label><caption><p><offsets xml_i="31377" xml_f="31480" txt_i="17818" txt_f="17921">Effect of the CORE andCQR-300 on plasma and urinary malondialdehyde, 5-HT, and plasma creatinine levels</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><offsets xml_i="31580" xml_f="31587" txt_i="17923" txt_f="17930">Group 1</offsets><break></break><offsets xml_i="31602" xml_f="31611" txt_i="17930" txt_f="17936">BMI&gt;30</offsets><break></break><offsets xml_i="31626" xml_f="31633" txt_i="17936" txt_f="17943">Placebo</offsets><break></break><offsets xml_i="31648" xml_f="31668" txt_i="17943" txt_f="17963">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="31702" xml_f="31709" txt_i="17964" txt_f="17971">Group 2</offsets><break></break><offsets xml_i="31724" xml_f="31733" txt_i="17971" txt_f="17977">BMI&gt;30</offsets><break></break><offsets xml_i="31748" xml_f="31752" txt_i="17977" txt_f="17981">CORE</offsets><break></break><offsets xml_i="31767" xml_f="31791" txt_i="17981" txt_f="18005">(no dietary restriction)</offsets></td><td align="left" colspan="2"><offsets xml_i="31825" xml_f="31832" txt_i="18006" txt_f="18013">Group 3</offsets><break></break><offsets xml_i="31847" xml_f="31856" txt_i="18013" txt_f="18019">BMI&gt;30</offsets><break></break><offsets xml_i="31871" xml_f="31875" txt_i="18019" txt_f="18023">CORE</offsets><break></break><offsets xml_i="31890" xml_f="31910" txt_i="18023" txt_f="18043">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="31944" xml_f="31951" txt_i="18044" txt_f="18051">Group 4</offsets><break></break><offsets xml_i="31966" xml_f="31975" txt_i="18051" txt_f="18057">BMI&gt;30</offsets><break></break><offsets xml_i="31990" xml_f="31997" txt_i="18057" txt_f="18064">CQR-300</offsets><break></break><offsets xml_i="32012" xml_f="32032" txt_i="18064" txt_f="18084">(2100 Kcal/day diet)</offsets></td><td align="left" colspan="2"><offsets xml_i="32066" xml_f="32073" txt_i="18085" txt_f="18092">Group 5</offsets><break></break><offsets xml_i="32088" xml_f="32099" txt_i="18092" txt_f="18103">BMI 24–29.9</offsets><break></break><offsets xml_i="32114" xml_f="32118" txt_i="18103" txt_f="18107">CORE</offsets><break></break><offsets xml_i="32133" xml_f="32157" txt_i="18107" txt_f="18131">(no dietary restriction)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="32203" xml_f="32215" txt_i="18132" txt_f="18144">Time (weeks)</offsets></td><td align="left"><offsets xml_i="32237" xml_f="32242" txt_i="18145" txt_f="18150">T = 0</offsets></td><td align="left"><offsets xml_i="32264" xml_f="32269" txt_i="18151" txt_f="18156">T = 6</offsets></td><td align="left"><offsets xml_i="32291" xml_f="32296" txt_i="18157" txt_f="18162">T = 0</offsets></td><td align="left"><offsets xml_i="32318" xml_f="32323" txt_i="18163" txt_f="18168">T = 8</offsets></td><td align="left"><offsets xml_i="32345" xml_f="32350" txt_i="18169" txt_f="18174">T = 0</offsets></td><td align="left"><offsets xml_i="32372" xml_f="32377" txt_i="18175" txt_f="18180">T = 8</offsets></td><td align="left"><offsets xml_i="32399" xml_f="32404" txt_i="18181" txt_f="18186">T = 0</offsets></td><td align="left"><offsets xml_i="32426" xml_f="32431" txt_i="18187" txt_f="18192">T = 6</offsets></td><td align="left"><offsets xml_i="32453" xml_f="32458" txt_i="18193" txt_f="18198">T = 0</offsets></td><td align="left"><offsets xml_i="32480" xml_f="32485" txt_i="18199" txt_f="18204">T = 8</offsets></td></tr><tr><td align="left"><offsets xml_i="32516" xml_f="32535" txt_i="18205" txt_f="18224">Plasma MDA (μmol/L)</offsets></td><td align="left"><offsets xml_i="32557" xml_f="32566" txt_i="18225" txt_f="18234">1.8 ± 0.1</offsets></td><td align="left"><offsets xml_i="32588" xml_f="32597" txt_i="18235" txt_f="18244">1.7 ± 0.1</offsets></td><td align="left"><offsets xml_i="32619" xml_f="32628" txt_i="18245" txt_f="18254">1.8 ± 0.6</offsets></td><td align="left"><offsets xml_i="32650" xml_f="32660" txt_i="18255" txt_f="18265">1.0 ± 0.5*</offsets></td><td align="left"><offsets xml_i="32682" xml_f="32691" txt_i="18266" txt_f="18275">1.9 ± 0.9</offsets></td><td align="left"><offsets xml_i="32713" xml_f="32724" txt_i="18276" txt_f="18287">1.1 ± 0.6 *</offsets><sup><offsets xml_i="32729" xml_f="32730" txt_i="18287" txt_f="18288">†</offsets></sup></td><td align="left"><offsets xml_i="32758" xml_f="32767" txt_i="18289" txt_f="18298">1.6 ± 0.2</offsets></td><td align="left"><offsets xml_i="32789" xml_f="32799" txt_i="18299" txt_f="18309">1.0 ± 0.4*</offsets></td><td align="left"><offsets xml_i="32821" xml_f="32830" txt_i="18310" txt_f="18319">1.8 ± 0.3</offsets></td><td align="left"><offsets xml_i="32852" xml_f="32862" txt_i="18320" txt_f="18330">1.2 ± 0.5*</offsets></td></tr><tr><td align="left"><offsets xml_i="32893" xml_f="32915" txt_i="18331" txt_f="18353">Urinary MDA (μmol/day)</offsets></td><td align="left"><offsets xml_i="32937" xml_f="32951" txt_i="18354" txt_f="18368">3476.2 ± 211.7</offsets></td><td align="left"><offsets xml_i="32973" xml_f="32987" txt_i="18369" txt_f="18383">3492.2 ± 188.4</offsets></td><td align="left"><offsets xml_i="33009" xml_f="33023" txt_i="18384" txt_f="18398">3864.3 ± 238.4</offsets></td><td align="left"><offsets xml_i="33045" xml_f="33060" txt_i="18399" txt_f="18414">4325.1 ± 167.5*</offsets></td><td align="left"><offsets xml_i="33082" xml_f="33096" txt_i="18415" txt_f="18429">4022.1 ± 148.1</offsets></td><td align="left"><offsets xml_i="33118" xml_f="33132" txt_i="18430" txt_f="18444">4485.8 ± 203.3</offsets></td><td align="left"><offsets xml_i="33154" xml_f="33168" txt_i="18445" txt_f="18459">3416.2 ± 110.9</offsets></td><td align="left"><offsets xml_i="33190" xml_f="33204" txt_i="18460" txt_f="18474">3581.5 ± 200.2</offsets></td><td align="left"><offsets xml_i="33226" xml_f="33240" txt_i="18475" txt_f="18489">3593.8 ± 116.5</offsets></td><td align="left"><offsets xml_i="33262" xml_f="33276" txt_i="18490" txt_f="18504">3971.0 ± 104.5</offsets></td></tr><tr><td align="left"><offsets xml_i="33307" xml_f="33327" txt_i="18505" txt_f="18525">Plasma 5-HT (mgl/dl)</offsets></td><td align="left"><offsets xml_i="33349" xml_f="33359" txt_i="18526" txt_f="18536">30.6 ± 1.9</offsets></td><td align="left"><offsets xml_i="33381" xml_f="33391" txt_i="18537" txt_f="18547">35.8 ± 2.1</offsets></td><td align="left"><offsets xml_i="33413" xml_f="33423" txt_i="18548" txt_f="18558">32.5 ± 1.9</offsets></td><td align="left"><offsets xml_i="33445" xml_f="33456" txt_i="18559" txt_f="18570">42.4 ± 3.4*</offsets></td><td align="left"><offsets xml_i="33478" xml_f="33488" txt_i="18571" txt_f="18581">38.4 ± 1.5</offsets></td><td align="left"><offsets xml_i="33510" xml_f="33520" txt_i="18582" txt_f="18592">53.4 ± 3.6</offsets><sup><offsets xml_i="33525" xml_f="33526" txt_i="18592" txt_f="18593">†</offsets></sup></td><td align="left"><offsets xml_i="33554" xml_f="33564" txt_i="18594" txt_f="18604">35.4 ± 1.7</offsets></td><td align="left"><offsets xml_i="33586" xml_f="33597" txt_i="18605" txt_f="18616">54.3 ± 2.9*</offsets></td><td align="left"><offsets xml_i="33619" xml_f="33629" txt_i="18617" txt_f="18627">33.1 ± 3.7</offsets></td><td align="left"><offsets xml_i="33651" xml_f="33662" txt_i="18628" txt_f="18639">43.2 ± 2.1*</offsets></td></tr><tr><td align="left"><offsets xml_i="33693" xml_f="33718" txt_i="18640" txt_f="18665">Plasma creatinine (mg/dl)</offsets></td><td align="left"><offsets xml_i="33740" xml_f="33750" txt_i="18666" txt_f="18676">25.7 ± 3.8</offsets></td><td align="left"><offsets xml_i="33772" xml_f="33782" txt_i="18677" txt_f="18687">27.3 ± 1.4</offsets></td><td align="left"><offsets xml_i="33804" xml_f="33814" txt_i="18688" txt_f="18698">25.9 ± 1.8</offsets></td><td align="left"><offsets xml_i="33836" xml_f="33846" txt_i="18699" txt_f="18709">31.8 ± 2.1</offsets></td><td align="left"><offsets xml_i="33868" xml_f="33878" txt_i="18710" txt_f="18720">24.4 ± 3.2</offsets></td><td align="left"><offsets xml_i="33900" xml_f="33910" txt_i="18721" txt_f="18731">28.9 ± 1.2</offsets></td><td align="left"><offsets xml_i="33932" xml_f="33942" txt_i="18732" txt_f="18742">27.2 ± 2.2</offsets></td><td align="left"><offsets xml_i="33964" xml_f="33975" txt_i="18743" txt_f="18754">33.6 ± 1.4*</offsets></td><td align="left"><offsets xml_i="33997" xml_f="34007" txt_i="18755" txt_f="18765">29.0 ± 0.8</offsets></td><td align="left"><offsets xml_i="34029" xml_f="34039" txt_i="18766" txt_f="18776">33.8 ± 1.2</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="34085" xml_f="34215" txt_i="18777" txt_f="18904">Values are means ± SD, comparing starting point to end point, significant differences were at *p &lt; 0.05 for the same treatment.</offsets></p></table-wrap-foot></table-wrap></sec></sec><sec><title><offsets xml_i="34274" xml_f="34284" txt_i="18907" txt_f="18917">Discussion</offsets></title><p><offsets xml_i="34295" xml_f="34581" txt_i="18918" txt_f="19204">The role of antioxidants from natural products in degenerative disease has attracted more interest on natural products research. In this study, we evaluated the antioxidant potential of CORE and CQR-300 on obesity-induced oxidative stress. The parent plant in these two formulations is </offsets><italic><offsets xml_i="34589" xml_f="34611" txt_i="19204" txt_f="19226">Cissus quandrangularis</offsets></italic><offsets xml_i="34620" xml_f="34651" txt_i="19226" txt_f="19257">. The formulation had a higher </offsets><italic><offsets xml_i="34659" xml_f="34668" txt_i="19257" txt_f="19266">in vitro </offsets></italic><offsets xml_i="34677" xml_f="34994" txt_i="19266" txt_f="19583">antioxidant potential than CQR-300 irrespective of the method used for the assay. The high antioxidant potential of CORE may be due to its composition. It contains some tea polyphenols and selenium that are potential antioxidants and thus complement the antioxidant potential of the parent plant in this formulation (</offsets><italic><offsets xml_i="35002" xml_f="35024" txt_i="19583" txt_f="19605">Cissus quandrangularis</offsets></italic><offsets xml_i="35033" xml_f="35092" txt_i="19605" txt_f="19664">). On the other hand, CQR-300 is a standardized extract of </offsets><italic><offsets xml_i="35100" xml_f="35123" txt_i="19664" txt_f="19687">Cissus quandrangularis </offsets></italic><offsets xml_i="35132" xml_f="35167" txt_i="19687" txt_f="19722">and no antioxidant was added to it.</offsets></p><p><offsets xml_i="35174" xml_f="35376" txt_i="19723" txt_f="19925">Obesity may induce systemic oxidative stress, and increased oxidative stress in accumulated fat is one of the underlying causes of dysregulation of adipocytokines and development of metabolic syndrome [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="35407" xml_f="35408" txt_i="19925" txt_f="19926">6</offsets></xref><offsets xml_i="35415" xml_f="35497" txt_i="19926" txt_f="20008">]. Oxidative stress plays critical roles in the pathogenesis of various diseases [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="35529" xml_f="35531" txt_i="20008" txt_f="20010">36</offsets></xref><offsets xml_i="35538" xml_f="36336" txt_i="20010" txt_f="20805">]. In order to investigate if oxidative stress was increased in the obese participants, we measured lipid peroxidation (which represent the plasma TBARS) and the carbonyl compounds as markers of oxidative injury, which correlates with the BMI. The high plasma concentration of TBARS and carbonyl compounds was an indication of oxidative stress in the obese and overweight participants. These concentrations were significantly (p &lt; 0.01) reduced after treatment, with CORE being more effective than CQR-300. These samples may function through two mechanisms: either by scavenging free radicals to reduce oxidative stress, or by clearing the plasma of the products that are themselves potential oxidants. These activities may be attributed to the polyphenols present in the different formulations.</offsets></p><p><offsets xml_i="36343" xml_f="36547" txt_i="20806" txt_f="21010">The use of CORE and CQR-300 during the study period brought about a significant reduction in the weight and BMI of obese patients. This loss in weight was comparable to that observed with cissus studies [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="36579" xml_f="36581" txt_i="21010" txt_f="21012">21</offsets></xref><offsets xml_i="36588" xml_f="36617" txt_i="21012" txt_f="21041">], sibutramine for one year [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="36649" xml_f="36651" txt_i="21041" txt_f="21043">37</offsets></xref><offsets xml_i="36658" xml_f="36698" txt_i="21043" txt_f="21083">], and orlistat for 6 months or 1 year [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="36730" xml_f="36732" txt_i="21083" txt_f="21085">38</offsets></xref><offsets xml_i="36739" xml_f="36740" txt_i="21085" txt_f="21086">,</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="36772" xml_f="36774" txt_i="21086" txt_f="21088">39</offsets></xref><offsets xml_i="36781" xml_f="37030" txt_i="21088" txt_f="21337">]. This reduction in BMI was accompanied by an increase in HDL-cholesterol, and corroborates earlier work that showed an inverse relation between BMI and HDL-cholesterol, the latter imparting possible health benefits in overweight and obese people [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="37062" xml_f="37064" txt_i="21337" txt_f="21339">40</offsets></xref><offsets xml_i="37071" xml_f="37072" txt_i="21339" txt_f="21340">,</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="37104" xml_f="37106" txt_i="21340" txt_f="21342">41</offsets></xref><offsets xml_i="37113" xml_f="37363" txt_i="21342" txt_f="21592">]. The increase in the concentration of HDL-cholesterol and a decrease in the concentration of LDL-cholesterol could lead to a lowering of the atherogenicity and therefore a significant reduction in the potential incidence of coronary heart disease [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="37395" xml_f="37397" txt_i="21592" txt_f="21594">42</offsets></xref><offsets xml_i="37404" xml_f="37479" txt_i="21594" txt_f="21669">] (54% reduction of risk for a 0.6 mmol/L reduction of serum cholesterol) [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="37511" xml_f="37513" txt_i="21669" txt_f="21671">43</offsets></xref><offsets xml_i="37520" xml_f="37663" txt_i="21671" txt_f="21814">]. A reduction of fasting blood glucose levels as well as MDA levels have been previously reported to accompany weight loss in obese subjects [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="37695" xml_f="37697" txt_i="21814" txt_f="21816">39</offsets></xref><offsets xml_i="37704" xml_f="37974" txt_i="21816" txt_f="22086">]. The above observation could be linked to an increase in circulating creatinine and serotonin over the eight-week trial period. Serotonin is known to have a positive effect on mood and to reduce binge eating, which is common in obese people. Several previous studies [</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="38006" xml_f="38008" txt_i="22086" txt_f="22088">44</offsets></xref><offsets xml_i="38015" xml_f="38016" txt_i="22088" txt_f="22089">,</offsets><xref ref-type="bibr" rid="B45"><offsets xml_i="38048" xml_f="38050" txt_i="22089" txt_f="22091">45</offsets></xref><offsets xml_i="38057" xml_f="38265" txt_i="22091" txt_f="22299">] have shown a direct link between serotonin levels and weight loss. On the other hand, an increase in creatinine concentrations parallels an increase in lean muscle mass and a probable reduction in body fat.</offsets></p><p><offsets xml_i="38272" xml_f="38285" txt_i="22300" txt_f="22313">Furthermore, </offsets><italic><offsets xml_i="38293" xml_f="38302" txt_i="22313" txt_f="22322">in vitro </offsets></italic><offsets xml_i="38311" xml_f="38378" txt_i="22322" txt_f="22389">studies (submitted in a different publication) show the ability of </offsets><italic><offsets xml_i="38386" xml_f="38408" txt_i="22389" txt_f="22411">Cissus quadrangularis </offsets></italic><offsets xml_i="38417" xml_f="38625" txt_i="22411" txt_f="22619">extracts to inhibit pancreatic lipase by approximately 60%, alpha-amylase by approximately 90%, as well as alpha-glucosidase by approximately 39%, all of which could contribute to weight reduction in obesity.</offsets></p></sec><sec><title><offsets xml_i="38647" xml_f="38657" txt_i="22621" txt_f="22631">Conclusion</offsets></title><p><offsets xml_i="38668" xml_f="39283" txt_i="22632" txt_f="23247">The CORE and CQR-300 (300 mg daily) brought about a significantly greater weight loss than placebo during the study period in obese individuals. This was accompanied by a significant improvement in the lipid profiles, blood sugar profiles, and serotonin profiles of study participants. They could have additional properties as antioxidants against oxidative stress in obese individuals. Thus, CQR-300 as well as CORE possesses antioxidant and free radical scavenging properties that could have applications in metabolic as well as other physiological complications in which there is an increase in oxidative stress.</offsets></p><p><offsets xml_i="39290" xml_f="39371" txt_i="23248" txt_f="23329">These new findings warrant further exploration into the active phytonutrients of </offsets><italic><offsets xml_i="39379" xml_f="39401" txt_i="23329" txt_f="23351">Cissus quadrangularis </offsets></italic><offsets xml_i="39410" xml_f="39499" txt_i="23351" txt_f="23440">and the potential of its newly discovered weight loss and cardiovascular health benefits.</offsets></p></sec><sec><title><offsets xml_i="39521" xml_f="39543" txt_i="23442" txt_f="23464">Authors' contributions</offsets></title><p><offsets xml_i="39554" xml_f="39798" txt_i="23465" txt_f="23709">JO conceived, designed, and coordinated the work, as well as drafted the manuscript; DM and GF carried out analytical work; YS carried out analytical and statistical analyses of data; GA participated in the design and editing of the manuscript.</offsets></p><p><offsets xml_i="39805" xml_f="39855" txt_i="23710" txt_f="23760">All authors have read and approved the manuscript.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The LNNB is grateful to Soy Labs (Fairfield, California, USA) for providing the cissus formulation (CORE) and AlbumaSoy™, and to Gateway Health Alliances Inc. (Fairfield, California, USA) for preparing and supplying the <italic>Cissus quadrangularis </italic>extract (CQR-300).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="other"><person-group person-group-type="author"><name><surname>McGill</surname><given-names>HC</given-names><suffix>Jr</suffix></name><name><surname>C McMahan</surname><given-names>A</given-names></name><name><surname>Herderick</surname><given-names>EE</given-names></name><name><surname>Zieske</surname><given-names>AW</given-names></name><name><surname>Malcom</surname><given-names>GT</given-names></name><name><surname>Tracy</surname><given-names>RE</given-names></name><name><surname>Strong</surname><given-names>JP</given-names></name></person-group><article-title>Obesity Accelerates the Progression of Coronary Atherosclerosis in Young Men</article-title><source>Circulation</source><year>2002</year><fpage>105</fpage><ext-link ext-link-type="uri" xlink:href="http://www.circulationaha.org"></ext-link></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montague</surname><given-names>CT</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name></person-group><article-title>The perils of portliness: causes and consequences of visceral adiposity</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>883</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">10866038</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances</article-title><source>Ann N Y Acad Sci</source><year>1999</year><volume>892</volume><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">10842660</pub-id><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb07793.x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group><article-title>Obesity and the regulation of energy balance</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">11239410</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00240-9</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>BB</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group><article-title>Obesity and insulin resistance</article-title><source>J Clin Invest</source><year>2000</year><volume>106</volume><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">10953022</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Shimabukuro</surname><given-names>M</given-names></name><name><surname>Iwaki</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>O</given-names></name><name><surname>Makishima</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name></person-group><article-title>Increased oxidative stress in obesity and its impact on metabolic syndrome</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>1752</fpage><lpage>1761</lpage><pub-id pub-id-type="pmid">15599400</pub-id><pub-id pub-id-type="doi">10.1172/JCI200421625</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Dietz</surname><given-names>WH</given-names></name></person-group><article-title>Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>356</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">11790215</pub-id><pub-id pub-id-type="doi">10.1001/jama.287.3.356</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isomaa</surname><given-names>B</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Forsen</surname><given-names>B</given-names></name><name><surname>Lahti</surname><given-names>K</given-names></name><name><surname>Nissen</surname><given-names>M</given-names></name><name><surname>Taskinen</surname><given-names>M</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Cardiovascular morbidity and mortality associated with the metabolic syndrome</article-title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">11315831</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Brewer</surname><given-names>HB</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Lefant</surname><given-names>C</given-names></name></person-group><article-title>Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">14744958</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000111245.75752.C6</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>Rk</given-names></name><name><surname>Kelly</surname><given-names>FG</given-names></name></person-group><article-title>Evidence for increased oxidative damage in patients with cystic fibrosis</article-title><source>Paediatr Res</source><year>1994</year><volume>36</volume><fpage>487</fpage><lpage>93</lpage></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gutteridge</surname><given-names>JM</given-names></name><name><surname>Swain</surname><given-names>J</given-names></name></person-group><article-title>Lipoprotein oxidation: the 'fruit and vegetable gradient' and heart disease</article-title><source>Br J Biomed Sci</source><year>1993</year><volume>50</volume><fpage>284</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8241843</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mustafa</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Ksonen</surname><given-names>Laa</given-names></name></person-group><article-title>Diabetes, oxidative stress and physical exercise</article-title><source>Journal sports Sc Med</source><year>2002</year><volume>1</volume><fpage>1</fpage><lpage>14</lpage></citation></ref><ref id="B13"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Lean</surname><given-names>M</given-names></name><name><surname>Burns</surname><given-names>J</given-names></name></person-group><article-title>Tentatives pharmacologiques et nutritionnelles pour corriger le stress oxydant</article-title><source>Flammarion, medecine science journée de diabetologie</source><year>2001</year><fpage>87</fpage><lpage>96</lpage></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ngondi</surname><given-names>JL</given-names></name><name><surname>Oben</surname><given-names>J</given-names></name><name><surname>Musoro</surname><given-names>FD</given-names></name><name><surname>Etame</surname><given-names>SLH</given-names></name><name><surname>Mbanya</surname><given-names>D</given-names></name></person-group><article-title>The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon</article-title><source>Aids Research and Therapy</source><year>2006</year><volume>3</volume><fpage>19</fpage><pub-id pub-id-type="pmid">16859567</pub-id><pub-id pub-id-type="doi">10.1186/1742-6405-3-19</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>D</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Carew</surname><given-names>TE</given-names></name><name><surname>Khoo</surname><given-names>JC</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><article-title>Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity</article-title><source>N Eng J Med</source><year>1989</year><volume>320</volume><fpage>915</fpage><lpage>924</lpage></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>EN</given-names></name><name><surname>Waterhouse</surname><given-names>AL</given-names></name><name><surname>TeissedreSpt</surname><given-names>PL</given-names></name></person-group><article-title>Principal Phenolic Phytochemicals in Selected California Wines and Their Antioxidant Activity in Inhibiting Oxidation of Human Low-Density Lipoproteins</article-title><source>J Agric Food Chem</source><year>1995</year><volume>43</volume><fpage>890</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1021/jf00052a008</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanner</surname><given-names>Jb</given-names></name><name><surname>Frankel</surname><given-names>JE</given-names></name><name><surname>Granit</surname><given-names>RBG</given-names></name><name><surname>Kinsellatss</surname><given-names>JE</given-names></name></person-group><article-title>Natural Antioxidants in Grapes and Wines</article-title><source>J Agric Food Chem</source><year>1994</year><volume>42</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1021/jf00037a010</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teissedre</surname><given-names>PL</given-names></name><name><surname>Frankel</surname><given-names>EN</given-names></name><name><surname>Waterhouse</surname><given-names>AL</given-names></name><name><surname>Peleg</surname><given-names>H</given-names></name><name><surname>German</surname><given-names>JB</given-names></name></person-group><article-title>Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and wines</article-title><source>J Sci Food Agric</source><year>1996</year><volume>70</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0010(199601)70:1&lt;55::AID-JSFA471&gt;3.0.CO;2-X</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>AgborA</given-names></name><name><surname>Oben</surname><given-names>JuliusE</given-names></name><name><surname>Ngogang</surname><given-names>JeanneY</given-names></name><name><surname>Xinxing</surname><given-names>Cai</given-names></name><name><surname>Vinson</surname><given-names>JoeA</given-names></name></person-group><article-title>Antioxidant Capacity of Some Herbs/spices from Cameroon. A Comparative study of two Methods</article-title><source>J Agri and Food Chem</source><year>2005</year><volume>53</volume><fpage>6819</fpage><lpage>6824</lpage><pub-id pub-id-type="doi">10.1021/jf050445c</pub-id></citation></ref><ref id="B20"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>AgborA</given-names></name><name><surname>Vinson</surname><given-names>JoeA</given-names></name><name><surname>Oben</surname><given-names>JuliusE</given-names></name><name><surname>Ngogang</surname><given-names>JeanneY</given-names></name></person-group><article-title>comparative study of the in vitro antioxidant activity of white and black pepper</article-title><source>Nutr Res</source><comment></comment></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oben</surname><given-names>J</given-names></name><name><surname>Kuate</surname><given-names>D</given-names></name><name><surname>Agbor</surname><given-names>G</given-names></name><name><surname>Momo</surname><given-names>C</given-names></name><name><surname>Talla</surname><given-names>X</given-names></name></person-group><article-title>The use of a cissus quadrangularis formulation in the management of weight loss and metabolic syndrome</article-title><source>Lipids in Health and Disease</source><year>2006</year><volume>5</volume><fpage>24</fpage><pub-id pub-id-type="pmid">16948861</pub-id><pub-id pub-id-type="doi">10.1186/1476-511X-5-24</pub-id></citation></ref><ref id="B22"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>AgborA</given-names></name><name><surname>Dieudonne</surname><given-names>Kuate</given-names></name><name><surname>Oben</surname><given-names>E</given-names></name><name><surname>Julius</surname><given-names>E</given-names></name></person-group><article-title>Medicinal plants can be good source of antioxidant: Case study of Cameroon</article-title><source>Pak J Biol Sci</source><year>2006</year></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mallika</surname><given-names>J</given-names></name><name><surname>Shyamala</surname><given-names>CSD</given-names></name></person-group><article-title><italic>In vitro </italic>and <italic>In vivo </italic>evaluation of free radical scavenging potential of <italic>Cissus quadrangularis</italic></article-title><source>Afri J of Biomed Res</source><year>2005</year><volume>8</volume><fpage>95</fpage><lpage>99</lpage></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>M</given-names></name><name><surname>Kaur</surname><given-names>N</given-names></name><name><surname>Bhutani</surname><given-names>K</given-names></name></person-group><article-title>Determination of marker constituents from <italic>Cissus quadrangularis Linn </italic>and their quantitation by HPTLC and HPLC</article-title><source>Phytochem Anal</source><year>2001</year><volume>12</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">11705245</pub-id><pub-id pub-id-type="doi">10.1002/pca.569</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jakikasem</surname><given-names>S</given-names></name><name><surname>Limsiriwong</surname><given-names>P</given-names></name><name><surname>Kajsongkarm</surname><given-names>T</given-names></name><name><surname>Sontorntanasart</surname><given-names>T</given-names></name></person-group><article-title>Phytochemical study of cissus quadrangularis</article-title><source>Thai J Pharm Sci</source><year>2000</year><volume>24</volume><fpage>25</fpage></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chidambara Murthy</surname><given-names>KN</given-names></name><name><surname>Vanitha</surname><given-names>A</given-names></name><name><surname>Mahadeva Swamy</surname><given-names>M</given-names></name><name><surname>Ravishankar</surname><given-names>GA</given-names></name></person-group><article-title>Antioxidant and antimicrobial activity of <italic>cissus quadrangularis </italic>L</article-title><source>Journal of Medicinal Foods</source><year>2003</year><volume>6</volume><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1089/109662003322233495</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>SS</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Gupta</surname><given-names>LP</given-names></name><name><surname>Datta</surname><given-names>IC</given-names></name></person-group><article-title>Studies on <italic>Cissus quadrangularis </italic>in experimental fracture Repair: Effect on Chemical Parameters in Blood</article-title><source>Ind J Med Res</source><year>1975</year><volume>63</volume><fpage>6</fpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singleton</surname><given-names>VL</given-names></name><name><surname>Orthofer</surname><given-names>R</given-names></name><name><surname>Lamuela-Raventòs</surname><given-names>RM</given-names></name></person-group><article-title>Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent</article-title><source>Methods Enzymol</source><year>1999</year><volume>299</volume><fpage>152</fpage><lpage>178</lpage></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benzie</surname><given-names>IFF</given-names></name><name><surname>Strain</surname><given-names>JJ</given-names></name></person-group><article-title>The Ferric Reducing Ability of Plasma (FRAP) as a measure of antioxidant power: The FRAP assay</article-title><source>Anal Biochem</source><year>1996</year><volume>239</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8660627</pub-id><pub-id pub-id-type="doi">10.1006/abio.1996.0292</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>GC</given-names></name><name><surname>Duh</surname><given-names>PD</given-names></name></person-group><article-title>Scavenging effect of methanolic extracts of peanut hulls on free-radical and active oxygen species</article-title><source>J Agri and Food Chem</source><year>1994</year><volume>42</volume><fpage>629</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1021/jf00039a005</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okhawa</surname><given-names>H</given-names></name><name><surname>Ohishi</surname><given-names>N</given-names></name><name><surname>Yagi</surname><given-names>K</given-names></name></person-group><article-title>Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction</article-title><source>Annals Biochemistry</source><year>1979</year><volume>95</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(79)90738-3</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Garland</surname><given-names>D</given-names></name><name><surname>Oliver</surname><given-names>CN</given-names></name></person-group><article-title>The determination of carbonyl content in oxidatively mordified proteins</article-title><source>Methods in Enzymology</source><year>1990</year><volume>186</volume><fpage>484</fpage><lpage>477</lpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>H</given-names></name><name><surname>Boemer</surname><given-names>M</given-names></name><name><surname>Heirli</surname><given-names>C</given-names></name></person-group><article-title>Serum creatinine determination without deproteinization</article-title><source>Clin Chim Acta</source><year>1972</year><volume>37</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">5022083</pub-id><pub-id pub-id-type="doi">10.1016/0009-8981(72)90432-9</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yagi</surname><given-names>K</given-names></name></person-group><article-title>A simple fluorometric assay for lipoperoxide in blood plasma</article-title><source>Biochemical Medicine</source><year>1976</year><volume>15</volume><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">962904</pub-id><pub-id pub-id-type="doi">10.1016/0006-2944(76)90049-1</pub-id></citation></ref><ref id="B35"><citation citation-type="book"><source>SPSS for Windows, Rel. 11.0.1</source><year>2001</year><publisher-name>Chicago: SPSS Inc</publisher-name></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group><article-title>Biochemistry and molecular cell biology of diabetic complications</article-title><source>Nature</source><year>2001</year><volume>414</volume><fpage>813</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">11742414</pub-id><pub-id pub-id-type="doi">10.1038/414813a</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>IG</given-names></name><name><surname>Goulder</surname><given-names>MA</given-names></name></person-group><article-title>Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity</article-title><source>J Fam Pract</source><year>2001</year><volume>50</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">11407998</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>DE</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Miles</surname><given-names>J</given-names></name><name><surname>Hollander</surname><given-names>P</given-names></name></person-group><article-title>Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated Type 2 diabetes</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1033</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">12032111</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yesilbursa</surname><given-names>D</given-names></name><name><surname>Serdar</surname><given-names>Z</given-names></name><name><surname>Serdar</surname><given-names>A</given-names></name><name><surname>Sarac</surname><given-names>M</given-names></name><name><surname>Jale</surname><given-names>C</given-names></name></person-group><article-title>Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels</article-title><source>International Journal of Obesity</source><year>2005</year><volume>29</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">15467775</pub-id><pub-id pub-id-type="doi">10.1038/sj.ijo.0802794</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pietrobelli</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>RC</given-names></name><name><surname>Capristo</surname><given-names>E</given-names></name><name><surname>Deckelbaum</surname><given-names>RJ</given-names></name><name><surname>Heymsfield</surname><given-names>SB</given-names></name></person-group><article-title>An independent, inverse association of high-density-lipoprotein-cholesterol concentration with nonadipose body mass</article-title><source>Am J Clin Nutr</source><year>1999</year><volume>69</volume><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">10197562</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knuiman</surname><given-names>JT</given-names></name><name><surname>West</surname><given-names>CE</given-names></name><name><surname>Burema</surname><given-names>J</given-names></name></person-group><article-title>Serum total and high density lipoprotein cholesterol concentrations and body mass index in adult men in 13 countries</article-title><source>Am J Epidemiol</source><year>1982</year><volume>116</volume><fpage>631</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">6182793</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>BA</given-names></name></person-group><article-title>Lipoprotein and atherogenicity: An overview of current mechanisms</article-title><source>Proceedings of the Nutrition Society</source><year>1999</year><volume>58</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">10343354</pub-id><pub-id pub-id-type="doi">10.1079/PNS19990022</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><collab>World Health Organisation Guidelines-International Society of Hypertension Mild Hypertension Liaison Committee</collab></person-group><article-title>World Health Organisation -International Society of Hypertension guidelines for the management of hypertension</article-title><source>J Hypertens</source><year>1999</year><volume>17</volume><fpage>151</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">10067786</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>A</given-names></name><name><surname>Day</surname><given-names>R</given-names></name><name><surname>Glickman-Weiss</surname><given-names>E</given-names></name><name><surname>Hegstad</surname><given-names>M</given-names></name><name><surname>Sampson</surname><given-names>B</given-names></name></person-group><article-title>Creatine supplementation raises anaerobic threshold</article-title><source>FASEB Journal</source><year>1997</year><volume>11</volume><fpage>A589</fpage><comment>(Abstract)</comment></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rockwell</surname><given-names>JA</given-names></name><name><surname>Rankin</surname><given-names>JW</given-names></name><name><surname>Toderico</surname><given-names>B</given-names></name></person-group><article-title>Creatine supplementation affects muscle creatine during energy restriction</article-title><source>Med Sci Sports Exer</source><year>2001</year><volume>33</volume><fpage>61</fpage><lpage>8</lpage></citation></ref></ref-list></back></article>